

AD\_\_\_\_\_

GRANT NUMBER DAMD17-98-1-8305

TITLE: Genomic Imprinting of the M6P/IGF2 Receptor: A Novel  
Breast Cancer Susceptibility Mechanism

PRINCIPAL INVESTIGATOR: Randy L. Jirtle, Ph.D.

CONTRACTING ORGANIZATION: Duke University Medical Center  
Durham, North Carolina 27710

REPORT DATE: July 1999

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000718 042

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Jul 98 - 30 Jun 99)
4. TITLE AND SUBTITLE Genomic Imprinting of the M6P/IGF2 Receptor: A Novel Breast Cancer Susceptibility Mechanism			5. FUNDING NUMBERS DAMD17-98-1-8305	
6. AUTHOR(S) Randy L. Jirtle, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Duke University Medical Center Durham, North Carolina 27710  E*Mail: jirtle@radonc.duke.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES  This report contains colored photographs				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) gene encodes for a receptor that plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors known to be involved in carcinogenesis. Our recent findings indicate that the M6P/IGF2R also functions as a tumor suppressor gene in liver, breast, and lung cancer. We hypothesize that M6P/IGF2R gene inactivation, by the novel mechanism of genomic imprinting, results in a non-Mendelian inherited predisposition to breast cancer. We have determined that the frequency of monoallelic M6P/IGF2R expression in breast cancer patients is higher than that of age-matched controls and are currently investigating the mechanism underlying the monoallelic expression in these patients. Based on exciting new information we have obtained for Wilms' tumors, we are presently testing the hypothesis that deficiency in M6P/IGF2R expression in these breast cancer patients is due to mutations in intron 10 of the M6P/IGF2R gene. These results would demonstrate a novel mechanism for the induction of breast carcinogenesis due to inactivation of the M6P/IGF2R gene through a post-transcriptional mechanism. Future studies will be directed at determining whether this is a result of spontaneous mutation or rather represents a heritable trait, which may be useful as a predictive and/or prognostic indicator of breast cancer susceptibility.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 43	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature                      7/16/99  
Date

## TABLE OF CONTENTS:

Front Cover .....	1
Standard form (SF) 298, Report Documentation Page.....	2
Foreword .....	3
Table of Contents .....	4
Introduction .....	5
Body .....	5
Key Research Accomplishments .....	6
Reportable Outcomes .....	6
Conclusions .....	6
References .....	7
Appendices .....	8

## INTRODUCTION:

The *mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R)* gene encodes for a receptor that plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors known to be involved in carcinogenesis (1, 2). Our recent findings indicate that the *M6P/IGF2R* also functions as a tumor suppressor gene in liver, breast, and lung cancer (2, 3, 4). We have determined that the frequency of monoallelic *M6P/IGF2R* expression in breast cancer patients is higher than that of age-matched controls and are currently investigating the mechanism underlying the monoallelic expression in these patients.

## BODY:

Since genomic imprinting leads to uniparental allelic expression, only a single mutation or recombination event would be necessary to functionally inactivate an imprinted tumor suppressor (2, 5). Thus, we have postulated that genomic imprinting of the *M6P/IGF2R* gene would result in a non-Mendelian inherited genetic predisposition to breast cancer. If genomic imprinting of the *M6P/IGF2R* predisposes women to breast cancer, then a significantly higher frequency of *M6P/IGF2R* gene imprinting should exist in breast cancer patients than in age-matched women with no history of cancer.

The initial findings of monoallelic *M6P/IGF2R* gene expression in 2/32 (6%) of the breast cancer patients prompted our investigation into the mechanism directing this phenotype. To eliminate any possibility of partial imprinting interfering with the interpretation of the experimental data, we initially focused our attention on Wilms' tumor patients, which have been documented to have clear and complete monoallelic expression of the *M6P/IGF2R* gene (6). Using four polymorphic markers within the *M6P/IGF2R* gene (mRNA nucleotide positions 901, 1197, 5002, and ACAA, a four-nucleotide insertion/deletion polymorphism in the 3' untranslated region), 2/8 (25%) Wilms' tumor patients were identified which were monoallelic at the cDNA level for the 5002 and ACAA informative loci. Surprisingly, these same two samples were found to have biallelic expression of *M6P/IGF2R* mRNA at the 901 and 1197 informative markers. Therefore, these two Wilms' tumor patients appear to have acquired a mutational event between the upstream (901 and 1197) and downstream (5002 and the ACAA) polymorphic markers which renders one transcript of the *M6P/IGF2R* inactive through truncation.

We have mapped the genomic region in which this mutational event occurred to within intron 10 of the *M6P/IGF2R* gene (7). Intron 10-specific sequence was present in cDNA from one allele of these samples using an intron 10 strand-specific oligonucleotide to prime reverse transcription followed by PCR amplification and nucleotide sequence analysis. It is not clear at this time if this unusual finding can be explained by a previously undefined mechanism which invokes aberrant regulation of genomic imprinting. Alternatively, there may be a mutational event which results in incorrect splicing of intron 10 with loss of downstream message. Similarly, transcriptional termination within intron 10 would produce an RNA transcript from which intron 10

cannot be excised. Current experimental efforts are directed at utilizing 3' RACE (Rapid Amplification of cDNA Ends) to map the 3' site of termination for this RNA. We are also presently in the process of cloning the entire intron 10 (5.5 kb) from both normal and tumor samples to allow for sequencing this intron in its entirety. This will enable us to unequivocally identify the mutation which leads to production of the truncated *M6P/IGF2R* transcript.

Once the mutation(s) within intron 10 is identified, we will return to the samples found to have "monoallelic expression" in breast cancer and evaluate these samples in light of the new information obtained. If these samples are also found to contain the intron 10 mutation, we will re-evaluate all of the breast cancer samples and the normal controls to determine the carriage rate for the intron 10 mutation. It is possible that this mutation may not be able to exert its effect alone, but may require other influential mutations in other genes to effect the production of the truncated RNA. If this is the case, this mutation could represent a predisposing, heritable factor for oncogenesis that might be present in a larger percentage of the population and be of value as a predictive tool for breast cancer susceptibility. In addition, the remaining expressed allele from the breast cancer patients showing "monoallelic expression" will be examined for inactivating mutations which may have directly led to the initiation of breast tumor formation.

#### **KEY RESEARCH ACCOMPLISHMENTS:**

- Monoallelic *M6P/IGF2R* 3' end gene expression was found in 2/32 (6.3%) of breast cancer patients, suggestive of either aberrant genomic imprinting and/or a posttranscriptional mechanism which results in the production of a single or truncated mRNA species.
- We have determined that in Wilms' tumor patients, a truncated *M6P/IGF2R* transcript is produced from one allele and have further mapped the site of truncation to within intron 10 of the *M6P/IGF2R* gene.

#### **REPORTABLE OUTCOMES:**

##### **Manuscripts:**

1. R.L. Jirtle, *Exp. Cell Res.* **248**, 18 (1999).
2. J.G. Falls, D.J. Pulford, A.A. Wylie, R.L. Jirtle, *Am. J. Path.*, **154**, 635 (1999).
3. J.K. Killian, R.L. Jirtle, *Mamm. Genome*, **10**, 74 (1999).
4. D.J. Pulford, J.G. Falls, J.K. Killian, R.L. Jirtle, *Mutat. Res.*, **436**, 59, (1999).

#### **CONCLUSIONS:**

The experimental results generated over the last support period have demonstrated a novel mechanism for production of a functionally monoallelic phenotype in both breast cancer and Wilms' tumor. The mapping of the 3' end of the truncated *M6P/IGF2R* mRNA in Wilms' tumor to within intron 10 suggests that a mutational event has occurred

within intron 10 which has in some way contributed to oncogenesis in these patients. Mapping of the specific mutation(s) within intron 10 that produce this phenotype will give us information that will be used to re-evaluate both the breast cancer samples and the normal controls to determine the frequency of this genetic alteration and if it is a predisposing factor for breast cancer. If this mutation is found to occur more frequently in the breast cancer samples, it may be useful as a diagnostic/prognostic tool for breast cancer development and survival. Furthermore, this unique mechanism for producing only one functionally active copy of the M6P/IGF2R may predispose individuals to a variety of cancers, and may be useful not only for screening purposes but also in contributing to our understanding of the complex etiology of tumor formation.

#### REFERENCES:

1. S. Kornfeld, *Annu. Rev. Biochem.* **61**, 307 (1992).
2. R. L. Jirtle, *Exp. Cell Res.* **248**, 18 (1999).
3. A. T. De Souza, T. Yamada, J. J. Mills, R. L. Jirtle, *FASEB J.* **11**, 60 (1997).
4. J. G. Falls, D. J. Pulford, A. A. Wylie, R. L. Jirtle, *Am. J. Pathol.* **154**, 635 (1999).
5. D. J. Pulford, J. G. Falls, J. K. Killian, R. L. Jirtle, *Mutat Res* **436**, 59 (1999).
6. Y. Q. Xu, P. Grundy, C. Polychronakos, *Oncogene* **14**, 1041 (1997).
7. J. K. Killian, R. L. Jirtle, *Mamm. Genome* **10**, 74 (1999).

## MINIREVIEW

## Genomic Imprinting and Cancer

Randy L. Jirtle<sup>1</sup>

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710

Although we inherit two copies of all genes, except those that reside on the sex chromosomes, there is a subset of these genes in which only the paternal or maternal copy is functional. This phenomenon of monoallelic, parent-of-origin expression of genes is termed genomic imprinting. Imprinted genes are normally involved in embryonic growth and behavioral development, but occasionally they also function inappropriately as oncogenes and tumor suppressor genes. The evidence that imprinted genes play a role in carcinogenesis will be discussed in this review. Additional information about imprinted genes can be found on the Genomic Imprinting Website at: (<http://www.geneimprint.com>). © 1999 Academic Press

## INTRODUCTION

Genomic imprinting is a non-Mendelian inherited epigenetic form of gene regulation that results in monoallelic expression. In contrast to the random allele inactivation that occurs for example at the *Xist* locus [1], the expressed allele for imprinted genes is dependent upon parental inheritance [for reviews see 2–4]. Thus, genomic imprinting is a phenomenon where the expression of a gene in this generation is dependent upon whether it resided in a male or female the past generation. Epigenetic events such as DNA methylation at CpG sites control the imprinting of genes [4]. Therefore, factors other than the sex of the parent could even modify the imprint process, thereby resulting in a Lamarckian-like inheritance of acquired traits. Such potential imprint-altering factors could include the parental level of nutrition, stress, and exposure to chemical and physical agents.

The existence of imprinted genes first became apparent when nuclear transplantation experiments demonstrated that diploid androgenotes derived from two

male pronuclei, and gynogenotes formed from two female pronuclei failed to develop properly during embryogenesis [5, 6]. Similarly, in humans complete hydatidiform moles which contain only paternal chromosomes produce primarily placental tissue, while dermoid cysts which contain only maternal chromosomes produce primarily embryonic tissue [7, 8]. These findings demonstrated that the mammalian genome contains autosomal genes that are only expressed from either the maternal or paternal allele. There are now more than 20 human imprinted genes identified ranging from growth factors to untranslated RNA, and it is postulated that 100 to 500 imprinted genes may exist [for review see 9].

The first endogenous imprinted gene identified was *Igf2* [10]. In 1991 De Chiara *et al.* [10] discovered that homozygous *Igf2*-null mice were approximately 40% smaller than wild-type mice when they were born, consistent with the known growth effects of *Igf2*. Importantly, the dwarfing phenotype was also observed in heterozygous mice, but only when the mutated allele was inherited from the father. This demonstrated that the *Igf2* gene is imprinted and expressed only from the paternal allele. *IGF2* is also imprinted in human tissues with the notable exception of the adult liver where expression is biallelic because of promoter switching after birth [11].

The second imprinted gene discovered was the maternally expressed *mannose 6-phosphate/insulin-like growth factor 2 receptor (M6p/Igf2r)* [12]. The *M6p/Igf2r* maps to the *Tme* locus on mouse chromosome 17 [12], and is the gene responsible for this maternal lethal effect [13]. The *M6p/Igf2r* encodes for a receptor that binds both M6P-containing glycoproteins and *Igf2* through independent binding sites [for review see 14]. The primary function of this receptor is the intracellular trafficking of phosphomannosyl glycoproteins from the Golgi apparatus to the lysosomes, and the internalization of *Igf2* and other extracellular ligands to the lysosomes for degradation [14]. *Igf2* signaling is not mediated by *M6p/Igf2r*, but rather it occurs principally

<sup>1</sup> To whom reprint requests should be addressed at Duke University Medical Center, Box 3433, Durham, NC 27710. Fax: (919) 684-5584. E-mail: [jirtle@radonc.duke.edu](mailto:jirtle@radonc.duke.edu).

through the Igf1 receptor and the insulin receptor [15, 16].

Thus, the bioavailability of Igf2 is controlled by a receptor that is also imprinted but expressed only from the maternal allele. The reciprocal imprinting of the *Igf2* and *M6p/Igf2r* genes suggested that the evolution of genomic imprinting may have resulted from a parent-offspring conflict to control fetal growth [17]. This parental "tug-of-war" model postulated by Haig [17] predicts that paternally expressed genes promote prenatal and postnatal growth while maternally expressed genes are growth suppressors. The identification of additional imprinted genes and their function will be required to determine whether this provocative model is adequate to explain the evolutionary pressure that resulted in the creation of genes that are functionally haploid [18].

Imprinted genes are not only important in prenatal [10, 19] and postnatal [20, 21] growth control, but also in behavioral development. People with Angelman syndrome, a congenital disease that evidence suggests is caused by the inactivation of the maternally expressed *UBE3A* (*ubiquitin protein ligase 3A*) gene, are severely retarded in addition to having ataxia, tremulousness, sleep disorders, seizures, and being hyperactive [for review see 9, 22]. *PEG1/MEST*, a member of the  $\alpha/\beta$ -hydroxylase fold family, is a paternally expressed gene that maps to human chromosome 7q32 [23]. *Peg1/Mest*(+/-)-deficient mice are viable and fertile; however, they exhibit growth retardation and increased lethality [24]. Interestingly, the females that inherit the mutated allele from their fathers also have a decreased reproductive fitness because of an abnormal nurturing behavior. It is presently unknown whether *PEG1/MEST* inactivation has a similar effect on maternal nurturing behavior in humans or what effect gene inactivation has in males. Furthermore, the *M6P/IGF2R* has been identified as the first putative "IQ gene," implicating imprinted genes in the development of cognitive ability [25]. Parent-of-origin inheritance effects suggest that imprinted genes are also a genetic determinant in autism [26], bipolar effective disorder [27, 28], and schizophrenia [29], to name only a few [30]. These results demonstrate that imprinted genes play a prominent role in behavioral genetics.

#### IMPRINTED ONCOGENES AND TUMOR SUPPRESSOR GENES

Imprinted genes are normally involved in embryonic growth and behavioral development; however, occasionally because of inappropriate expression, they also function as oncogenes and tumor suppressor genes. Loss of heterozygosity (LOH) or uniparental disomy (UPD) at an imprinted locus may result in the deletion

of the only functional copy of an imprinted tumor suppressor gene [9, 31]. Alternatively, loss of imprinting (LOI) or UPD at an imprinted locus may result in an increased expression of an imprinted proto-oncogene. Furthermore, mutational inactivation of an imprint control center could cause aberrant expression of multiple imprinted proto-oncogenes and/or tumor suppressor genes since imprinted genes often occur in chromosomal domains [32, 33]. Imprinted genes now implicated in human carcinogenesis include: *IGF2*, *WT1*, *p57<sup>KIP2</sup>*, *p73*, *NOEY2*, and *M6P/IGF2R* [9].

Aberrant genomic imprinting and its role in cancer are best exemplified by studies on Wilms' tumor, a sporadic and familial childhood kidney tumor that arises from metanephric blastemal cells. Direct genetic evidence linking tumorigenesis and aberrant imprinting was identified when 70% of Wilms' tumors were found to have biallelic expression of *IGF2* [34–36], a gene that encodes for a growth factor known to be oncogenic when overexpressed [37, 38]. Inactivation of the reciprocally imprinted *H19* gene was also present in a number of these cases [36] suggesting that LOI at the *IGF2* locus in Wilms' tumor could result from loss of *H19* expression [39, 40]. This postulate is supported by the finding that *H19*-null transgenic mice show biallelic expression of *IGF2* [41]. The coupling of biallelic *IGF2* gene expression with *H19* inactivation is even observed in phenotypically normal kidney tissue surrounding Wilms' tumors [42]. Thus, *H19* inactivation and the biallelic expression of *IGF2* appear to be linked and occur early in tumor development. Dereglulation of *IGF2* imprinting has now been shown to occur in over 20 different tumor types, demonstrating its fundamental mechanistic importance in carcinogenesis [9].

Another imprinted gene involved in Wilms' tumor formation is *WT1*, a tumor suppressor located at human chromosome 11p13 [43]. *WT1* is biallelically expressed in the kidney, heart, lung, liver, and intestine, but is expressed largely or exclusively from the maternal allele in fetal brain [44]. It is also imprinted in 40% of preterm placenta [44, 45]. Since the imprint status is not correlated with gestational age of the placenta [45], imprinting of the *WT1* gene in the placenta is a polymorphic trait. Imprinting at the *WT1* locus is also polymorphic in fibroblasts and lymphocytes, but the paternal rather than the maternal allele is expressed [46]. These findings suggest the interesting possibility that polymorphic imprinting of the *WT1* tumor suppressor gene could result in both tissue- and individual-dependent susceptibilities to cancer.

The maternally expressed cyclin-dependent kinase inhibitor, *p57<sup>KIP2</sup>*, maps to human chromosome 11p15.5 [47, 48]. Approximately 10% of Beckwith-Wiedemann syndrome patients have *p57<sup>KIP2</sup>* mutations, but *p57<sup>KIP2</sup>*

has not been found to be mutated in tumors [49, 50]. The maternal allele of *p57<sup>KIP2</sup>* is selectively lost in 85% of lung cancers with 11p15 deletions [51]; however, in Wilms' tumors with maternal loss of *p57<sup>KIP2</sup>*, the normally silent paternal allele is expressed [52]. This suggests that *p57<sup>KIP2</sup>* is not a tumor suppressor, at least in Wilms' tumor. Since the imprinting of *p57<sup>KIP2</sup>* is incomplete in humans with paternal expression occurring even in some tissues, the putative tumor suppressor function of *p57<sup>KIP2</sup>* needs to be further clarified.

*NOEY2* is a recently identified member of the *RAS* superfamily with high homology to both *RAS* and *RAP* [53]. It maps to human chromosome 1p31 and is expressed only from the paternal allele. LOH at this locus is observed in 41% of ovarian and breast cancers, and the paternally expressed allele is preferentially deleted. Furthermore, transfection of *NOEY2* into breast and ovarian tumor cells that normally lack expression suppresses growth. Thus, *NOEY2* appears to be an imprinted tumor suppressor gene whose function is frequently abrogated in ovarian and breast cancers.

*p73* is an imprinted, maternally expressed gene that encodes for a protein sharing considerable homology with the tumor suppressor *p53* [54]. It maps to human chromosome 1p36, a region containing a putative neuroblastoma tumor suppressor gene expressed predominantly from the maternal allele. The frequent loss of *p73* in neuroblastomas coupled with the demonstration that its overexpression inhibits growth suggested that *p73* is a tumor suppressor gene [55]. Additional studies with a variety of tumors, however, were unable to demonstrate either preferential loss of the expressed maternal allele or somatic mutations in the remaining allele. These findings suggest that *p73* is not the putative imprinted tumor suppressor present at this chromosomal location [56–62].

Monoallelic expression of *p73* has recently been demonstrated in normal lung and kidney tissue, whereas expression is biallelic in the tumors that develop in these tissues [63, 64]. The high frequency of LOI and imprint switching at the *p73* locus in lung cancer and renal cell carcinomas suggest that *p73* is involved in tumorigenesis through the activation of the silent allele and overexpression of wild-type *p73*. Consequently, *p73* may function as an oncogene rather than as a tumor suppressor gene as originally proposed. It would be ironic if both *p53* and *p73* were initially described to have an oncogenic function opposite to that which it possesses.


The *M6P/IGF2R*, at human chromosome location 6q26, is inactivated in a variety of tumors at the earliest stage of transformation [65–68]. It is mutated in 60% of dysplastic liver lesions and hepatocellular carcinomas (HCCs) of patients with or without hepatitis virus (HV) infection [65, 66, 68, 69]. The *M6P/IGF2R* is

also mutated in rat liver tumors induced with the genotoxic agent, diethylnitrosamine [70]. The gene contains a poly-G region that is a common mutational target in colon, gastric and endometrial tumors with mismatch repair deficiencies and microsatellite instability [71–73]. Moreover, the *M6P/IGF2R* is mutated in human gliomas that do not contain mutations in the *transforming growth factor  $\beta$  type II receptor* or *Bax* genes [73], and in 30% of human breast tumors [67]. Thus, the *M6P/IGF2R* has been shown to be frequently mutated in a number of different cancers.

Although gene imprinting is often conserved between mammalian species, the imprint status of the *M6P/IGF2R* in humans and rodents is strikingly different. The *M6p/Igf2r* is imprinted in mice [12] and rats [70], but imprinting at this locus appears to be a polymorphic trait in humans, with most individuals having biallelic expression [74–76]. The existence of individuals with an imprinted *M6P/IGF2R* tumor suppressor suggests that they may have increased susceptibility to tumor development because of aberrant imprint control. This postulate is supported by Xu *et al.* [77] who recently reported partial imprinting of the *M6P/IGF2R* in 50% of Wilms' tumor patients. Furthermore, only 1 hit rather than 2 hits would be required to inactivate the tumor suppressor function of the *M6p/Igf2r* in mice. This may in part explain why mice are more sensitive to tumor formation than humans. It also suggests that transgenic mice with biallelic expression of the *M6p/Igf2r* may be better human surrogates for carcinogen risk assessment than those presently employed.

The precise molecular mechanism for genomic imprinting of the *M6P/IGF2R* is not completely defined. Methylation of a CpG-rich region in intron 2 (region 2) of the expressed maternal allele carries the imprint signal for this gene in mice [78, 79], and the imprinting box in this region has also now been identified [80]. This region appears to function as the promoter of an antisense transcript that originates only from the repressed paternal allele. This indicates that a form of expression competition may regulate imprinting of the *M6p/Igf2r* gene in mice [79]. Region 2 of the human *M6P/IGF2R* also contains parent-of-origin methylation, but gene expression is biallelic [81, 82]. Consequently, humans and mice appear to possess an altered ability to "read" the *M6P/IGF2R* imprint marks.

*M6P/IGF2R* inactivation is an early event in liver carcinogenesis, occurring in the initiation rather than the progression stage of transformation (Fig. 1) [68]. Clonal expansion of normal-appearing, preneoplastic hepatocytes with a single *M6P/IGF2R* allele inactivated often occurs in patients chronically infected with hepatitis virus. These precancerous hepatocytes have an enhanced risk of developing into tumors because



**FIG. 1.** Oncogenesis model of hepatocellular carcinoma (HCC) development in patients with liver cirrhosis. (A) Normal human liver. (B) Chronic hepatitis virus infection and/or alcohol abuse results in hepatocyte loss (white areas), and the formation of preneoplastic hepatocytes in which a single allele of the *M6P/IGF2R* tumor suppressor gene is inactivated (●). (C) The preneoplastic, *M6P/IGF2R*-mutated hepatocytes preferentially regenerate and/or survive, forming clonal lesions (black areas) in the cirrhotic liver. (D) These clonal regions of preneoplastic hepatocytes (black areas) continue to expand as liver cirrhosis progresses. Approximately 60% of HCCs (large sphere) ultimately arise from this clonally expanded population of preneoplastic, *M6P/IGF2R*-mutated hepatocytes; both alleles of the *M6P/IGF2R* are commonly inactivated in the HCCs.

they ultimately give rise to more than 60% of human HCCs [65, 66, 68]. This suggests that a primary "initiation event" in human liver carcinogenesis is the inactivation of a single allele of the *M6P/IGF2R* gene. The "promotion event" in the transformation process is the clonal expansion of these phenotypically normal, *M6P/IGF2R*-mutated preneoplastic hepatocytes at high risk of completely losing the tumor suppressor function of this gene. All other oncogenic events observed in dysplastic to neoplastic liver lesions occur in the progression stage of transformation. The inactivation of the *M6P/IGF2R* is also an early event in breast cancer [67, 83], but it is unknown whether gene inactivation results in clonal growth in the breast as it does in the liver.

In conclusion, genomic imprinting is an epigenetic form of gene regulation that results in the expression of only one parental allele. Imprinted genes not only play an important role in embryogenesis and behavioral development but are also mechanistically involved in carcinogenesis. Because imprinted genes are functionally haploid, imprinted tumor suppressor genes and proto-oncogenes are particularly vulnerable to inactivation and activation, respectively. The imprinting of genes also varies between species, individuals, tissues, cells, and stage of embryonic development. Therefore,

the overall effect of genomic imprinting on cancer susceptibility and penetrance is potentially great.

This study was supported by NIH Grants CA25951 and ES08823, DOD Grant DAMD17-98-1-8305, Rohm & Haas Chemical Company, and Zeneca Pharmaceuticals.

# REFERENCES:

1. Brockdorff, N., and Duthie, S. M. (1998). X chromosome inactivation and the Xist gene. *Cell Mol. Life Sci.* **54**, 104–112.
2. Barlow, D. P. (1995). Gametic imprinting in mammals. *Science* **270**, 1610–1613.
3. Bartolomei, M. S., and Tilghman, S. M. (1997). Genomic imprinting in mammals. *Annu. Rev. Genet.* **31**, 493–525.
4. Constancia, M., Pickard, B., Kelsey, G., and Reik, W. (1998). Imprinting mechanisms. *Genome Res.* **8**, 881–900.
5. McGrath, J., and Solter, D. (1984). Completion of mouse embryogenesis requires both the maternal and paternal genomes. *Cell* **37**, 179–183.
6. Surani, M. A., Barton, S. C., and Norris, M. L. (1984). Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. *Nature* **308**, 548–550.
7. Kajii, T., and Ohama, K. (1977). Androgenetic origin of hydatidiform mole. *Nature* **268**, 633–634.
8. Ohama, K., Nomura, K., Okamoto, E., Fukuda, Y., Ihara, T., and Fujiwara, A. (1985). Origin of immature teratoma of the ovary. *Am. J. Obstet. Gynecol.* **152**, 896–900.

9. Falls, J. G., Pulford, D. J., Wylie, A. A., and Jirtle, R. L. (1999). Genomic imprinting: implications for human disease. *Am. J. Pathol.* **154**, 635–647.
10. DeChiara, T. M., Robertson, E. J., and Efstratiadis, A. (1991). Parental imprinting of the mouse insulin-like growth factor II gene. *Cell* **64**, 849–859.
11. Vu, T. H., and Hoffman, A. R. (1994). Promoter-specific imprinting of the human insulin-like growth factor-II gene. *Nature* **371**, 714–717.
12. Barlow, D. P., Stöger, R., Herrmann, B. G., Saito, K., and Schweifer, N. (1991). The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* **349**, 84–87.
13. Wang, Z. Q., Fung, M. R., Barlow, D. P., and Wagner, E. F. (1994). Regulation of embryonic growth and lysosomal targeting by the imprinted *Igf2/Mpr* gene. *Nature* **372**, 464–467.
14. Kornfeld, S. (1992). Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. *Annu. Rev. Biochem.* **61**, 307–330.
15. Czech, M. P., Lewis, R. E., and Corvera, S. (1989). Multifunctional glycoprotein receptors for insulin and the insulin-like growth factors. *Ciba Found. Symp.* **145**, 27–41.
16. Morrión, A., Valentinis, B., Xu, S.-Q., Yumet, G., Louvi, A., Efstratiadis, A., and Baserga, R. (1997). Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. *Proc. Natl. Acad. Sci. USA* **94**, 3777–3782.
17. Haig, D., and Graham, C. (1991). Genomic imprinting and the strange case of the insulin-like growth factor II receptor. *Cell* **64**, 1045–1046.
18. Hurst, L. D., and McVean, G. T. (1997). Growth effects of uniparental disomies and the conflict theory of genomic imprinting. *Trends Genet.* **13**, 436–443.
19. Sun, F. L., Dean, W. L., Kelsey, G., Allen, N. D., and Reik, W. (1997). Transactivation of *Igf2* in a mouse model of Beckwith-Wiedemann syndrome. *Nature* **389**, 809–815.
20. Nezer, C., Moreau, L., Brouwers, B., Coppieters, W., Detilleux, J., Hanset, R., Karim, L., Kvasz, A., Leroy, P., and Georges, M. (1999). An imprinted QTL with major effect on muscle mass and fat deposition maps to the *IGF2* locus in pigs. *Nat. Genet.* **21**, 155–156.
21. Jeon, J. T., Carlborg, O., Tornsten, A., Giuffa, E., Amarger, V., Chardon, P., Andersson-Eklund, L., Andersson, K., Hansson, I., Lundström, K., and Andersson, L. (1999). A paternally expressed QTL affecting skeletal and cardiac muscle mass in pigs maps to the *IGF2* locus. *Nat. Genet.* **21**, 157–158.
22. Lalande, M. (1996). Parental imprinting and human disease. *Annu. Rev. Genet.* **30**, 173–195.
23. Kobayashi, S., Kohda, T., Miyoshi, N., Kuroiwa, Y., Aisaka, K., Tsutsumi, O., Kaneko-Ishino, T., and Ishino, F. (1997). Human *PEG1/MEST*, an imprinted gene on chromosome 7. *Hum. Mol. Genet.* **6**, 781–786.
24. Lefebvre, L., Viville, S., Barton, S. C., Ishino, F., Keverne, E. B., and Surani, M. A. (1998). Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene *Mest*. *Nat. Genet.* **20**, 163–169.
25. Chorney, M. J., Chorney, K., Seese, N., Owen, M. J., Daniels, J., McGuffin, P., Thompson, L. A., Detterman, D. K., Benbow, C., Lubinski, D., Eley, T., and Plomin, R. (1998). A quantitative trait locus associated with cognitive ability in children. *Psych. Sci.* **9**, 159–166.
26. Cook, E. H., Jr., Lindgren, V., Leventhal, B. L., Courchesne, R., Lincoln, A., Shulman, C., Lord, C., and Courchesne, E. (1997). Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. *Am. J. Hum. Genet.* **60**, 928–934.
27. Grigoriu-Serbanescu, M., Wickramaratne, P. J., Hodge, S. E., Milea, S., and Mihailescu, R. (1997). Genetic anticipation and imprinting in bipolar I illness. *Br. J. Psychiatry* **170**, 162–166.
28. Kato, T., Winokur, G., Coryell, W., Keller, M. B., Endicott, J., and Rice, J. (1996). Parent-of-origin effect in transmission of bipolar disorder. *Am. J. Med. Genet.* **67**, 546–550.
29. Ohara, K., Xu, H. D., Mori, N., Suzuki, Y., Xu, D. S., and Wang, Z. C. (1997). Anticipation and imprinting in schizophrenia. *Biol. Psychiatry* **42**, 760–766.
30. Morison, I. M., and Reeve, A. E. (1998). A catalogue of imprinted genes and parent-of-origin effects in humans and animals. *Hum. Mol. Genet.* **7**, 1599–1609.
31. Pulford, D. J., Falls, J. G., Killian, J. K., and Jirtle, R. L. (1999). Polymorphisms, genomic imprinting and cancer susceptibility. *Mutat. Res.* **436**, 59–67.
32. Hendrich, B. D., and Huntington, F. W. (1995). Epigenetic regulation of gene expression: the effect of altered chromatin structure from yeast to mammals. *Hum. Mol. Genet.* **4**, 1765–1777.
33. Feil, R., and Kelsey, G. (1997). Genomic imprinting: A chromatin connection. *Am. J. Hum. Genet.* **61**, 1213–1219.
34. Ogawa, O., Eccles, M. R., Szeto, J., McNoe, L. A., Yun, K., Maw, M. A., Smith, P. J., and Reeve, A. E. (1993). Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. *Nature* **362**, 749–751.
35. Rainier, S., Johnson, L. A., Dobry, C. J., Ping, A. J., Grundy, P. E., and Feinberg, A. P. (1993). Relaxation of imprinted genes in human cancer. *Nature* **362**, 747–749.
36. Steenman, M. J. C., Rainier, S., Dobry, C. J., Grundy, P., Horon, I. L., and Feinberg, A. P. (1994). Loss of imprinting of *IGF2* is linked to reduced expression and abnormal methylation of *H19* in Wilms' tumour. *Nat. Genet.* **7**, 433–439.
37. Bates, P., Fisher, R., Ward, A., Richardson, L., Hill, D. J., and Graham, C. F. (1995). Mammary cancer in transgenic mice expressing insulin-like growth factor II (*IGF-II*). *Br. J. Cancer* **72**, 1189–1193.
38. Rogler, C. E., Yang, D., Rossetti, L., Donohoe, J., Alt, E., Chang, C. J., Rosenfeld, R., Neely, K., and Hintz, R. (1994). Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. *J. Biol. Chem.* **269**, 13779–13784.
39. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E., and Tycko, B. (1993). Tumor-suppressor activity of *H19*. *Nature* **365**, 764–767.
40. Webber, A. L., Ingram, R. S., Levorso, J. M., and Tilghman, S. M. (1998). Location of enhancers is essential for the imprinting of *H19* and *Igf2* genes. *Nature* **391**, 711–715.
41. Leighton, P. A., Ingram, R. S., Eggenschwiler, J., Efstratiadis, A., and Tilghman, S. M. (1995). Disruption of imprinting caused by deletion of the *H19* gene region in mice. *Nature* **375**, 34–39.
42. Okamoto, K., Morison, I. M., Taniguchi, T., and Reeve, A. E. (1997). Epigenetic changes at the insulin-like growth factor II/*H19* locus in developing kidney is an early event in Wilms tumorigenesis. *Proc. Natl. Acad. Sci. USA* **94**, 5367–5371.
43. Huff, V. (1998). Wilms tumor genetics. *Am. J. Med. Genet.* **79**, 260–267.
44. Jinno, Y., Yun, K., Nishiwaki, K., Kubota, T., Ogawa, O., Reeve, A. E., and Niikawa, N. (1994). Mosaic and polymorphic imprinting of the *WT1* gene in humans. *Nat. Genet.* **6**, 305–309.

45. Nishiwaki, K., Niikawa, N., and Ishikawa, M. (1997). Polymorphic and tissue-specific imprinting of the human Wilms tumor gene, WT1. *Jpn. J. Hum. Genet.* **42**, 205-211.
46. Mitsuya, K., Sui, H., Meguro, M., Kugoh, H., Jinno, Y., Niikawa, N., and Oshimura, M. (1997). Paternal expression of WT1 in human fibroblasts and lymphocytes. *Hum. Mol. Genet.* **6**, 2243-2246.
47. Hatada, I., Inazawa, J., Abe, T., Nakayama, M., Kaneko, Y., Jinno, Y., Niikawa, N., Ohashi, H., Fukushima, Y., Iida, K., Yutani, C., Takahashi, S., Chiba, Y., Ohishi, S., and Mukai, T. (1996). Genomic imprinting of human p57<sup>KIP2</sup> and its reduced expression in Wilms' tumors. *Hum. Mol. Genet.* **5**, 783-788.
48. Hatada, I., and Mukai, T. (1995). Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. *Nat. Genet.* **11**, 204-206.
49. Hatada, I., Ohashi, H., Fukushima, Y., Kaneko, Y., Inoue, M., Komoto, Y., Okada, A., Ohishi, S., Nabetani, A., Morisaki, H., Nakayama, M., Niikawa, N., and Mukai, T. (1996). An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. *Nat. Genet.* **14**, 171-173.
50. O'Keefe, D., Dao, D., Zhao, L., Sanderson, R., Warburton, D., Weiss, L., Anyane-Yeboah, K., and Tycko, B. (1997). Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. *Am. J. Hum. Genet.* **61**, 295-303.
51. Kondo, M., Matsuoka, S., Uchida, K., Osada, H., Nagatake, M., Takagi, K., Harper, J. W., Takahashi, T., and Elledge, S. J. (1996). Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. *Oncogene* **12**, 1365-1368.
52. Taniguchi, T., Okamoto, K., and Reeve, A. E. (1997). Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour. *Oncogene* **14**, 1201-1206.
53. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W. L., Gray, J. W., Siciliano, M., Mills, G. B., and Bast, R. C., Jr. (1999). NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. *Proc. Natl. Acad. Sci. USA* **96**, 214-219.
54. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* **90**, 809-819.
55. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. (1997). p73 is a human p53-related protein that can induce apoptosis. *Nature* **389**, 191-194.
56. Nomoto, S., Haruki, N., Kondo, M., Konishi, H., and Takahashi, T. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. *Cancer Res.* **58**, 1380-1383.
57. Kovalev, S., Marchenko, N., Swendeman, S., LaQuaglia, M., and Moll, U. M. (1998). Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. *Cell Growth Differ.* **9**, 897-903.
58. Nimura, Y., Mihara, M., Ichimiya, S., Sakiyama, S., Seki, N., Ohira, M., Nomura, N., Fujimori, M., Adachi, W., Amano, J., He, M., Ping, Y. M., and Nakagawara, A. (1998). p73, a gene related to p53, is not mutated in esophageal carcinomas. *Int. J. Cancer* **78**, 437-440.
59. Mai, M., Huang, H., Reed, C., Qian, C., Smith, J. S., Alderete, B., Jenkins, R., Smith, D. I., and Liu, W. (1998). Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. *Genomics* **51**, 359-363.
60. Sunahara, M., Ichimiya, S., Nimura, Y., Takada, N., Sakiyama, S., Sato, Y., Todo, S., Adachi, W., Amano, J., and Nakagawara, A. (1998). Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. *Int. J. Oncol.* **13**, 319-323.
61. Kroiss, M. M., Bosserhoff, A. K., Vogt, T., Buettner, R., Bogenrieder, T., Landthaler, M., and Stolz, W. (1998). Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. *Melanoma Res.* **8**, 504-509.
62. Tsao, H., Zhang, X., Majewski, P., and Haluska, F. G. (1999). Mutational and expression analysis of the p73 gene in melanoma cell lines. *Cancer Res.* **59**, 172-174.
63. Mai, M., Qian, C., Yokomizo, A., Tindall, D. J., Bostwick, D., Polychronakos, C., Smith, D. I., and Liu, W. (1998). Loss of imprinting and allele switching of p73 in renal cell carcinoma. *Oncogene* **17**, 1739-1741.
64. Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. I., and Liu, W. (1998). Activation of p73 silent allele in lung cancer. *Cancer Res.* **58**, 2347-2349.
65. De Souza, A. T., Hankins, G. R., Washington, M. K., Fine, R. L., Orton, T. C., and Jirtle, R. L. (1995). Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. *Oncogene* **10**, 1725-1729.
66. De Souza, A. T., Hankins, G. R., Washington, M. K., Orton, T. C., and Jirtle, R. L. (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nat. Genet.* **11**, 447-449.
67. Hankins, G. R., De Souza, A. T., Bentley, R. C., Patel, M. R., Marks, J. R., Iglehart, J. D., and Jirtle, R. L. (1996). M6P/IGF2 receptor: a candidate breast tumor suppressor gene. *Oncogene* **12**, 2003-2009.
68. Yamada, T., De Souza, A. T., Finkelstein, S., and Jirtle, R. L. (1997). Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. *Proc. Natl. Acad. Sci. USA* **94**, 10351-10355.
69. Piao, Z., Choi, Y., Park, C., Lee, W. J., Park, J. H., and Kim, H. (1997). Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. *Cancer Lett.* **120**, 39-43.
70. Mills, J. J., Falls, J. G., De Souza, A. T., and Jirtle, R. L. (1998). Imprinted M6p/Igf2 receptor is mutated in rat liver tumors. *Oncogene* **16**, 2797-2802.
71. Souza, R. F., Appel, R., Yin, J., Wang, S., Smolinski, K. N., Abraham, J. M., Zou, T.-T., Shi, Y.-Q., Lei, J., Cottrell, J., Cymes, K., Biden, K., Simms, L., Leggett, B., Lynch, P. M., Frazier, M., Powell, S. M., Harpaz, N., Sugimura, H., Young, J., and Meltzer, S. J. (1996). The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumours. *Nat. Genet.* **14**, 255-257.
72. Ouyang, H., Shiwa, H. O., Hagiwara, H., Miura, K., Abe, T., Kato, Y., Ohtani, H., Shiiba, K., Souza, R. F., Meltzer, S. J., and Horii, A. (1997). The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. *Cancer Res.* **57**, 1851-1854.
73. Leung, S. Y., Chan, T. L., Chung, L. P., Chan, A. S., Fan, Y. W., Hung, K. N., Kwong, W. K., Ho, J. W., and Yuen, S. T. (1998). Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. *Am. J. Pathol.* **153**, 1181-1188.

74. Kalscheuer, V. M., Mariman, E. C., Schepens, M. T., Rehder, H., and Ropers, H.-H. (1993). The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. *Nat. Genet.* **5**, 74–78.
75. Ogawa, O., McNoe, L. A., Eccles, M. R., Morison, I. M., and Reeve, A. E. (1993). Human insulin-like growth factor type I and type II receptors are not imprinted. *Hum. Mol. Genet.* **2**, 2163–2165.
76. Xu, Y., Goodyer, C. G., Deal, C., and Polychronakos, C. (1993). Functional polymorphism in the parental imprinting of the human IGF2R gene. *Biochem. Biophys. Res. Commun.* **197**, 747–754.
77. Xu, Y. Q., Grundy, P., and Polychronakos, C. (1997). Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. *Oncogene* **14**, 1041–1046.
78. Stöger, R., Kubicka, P., Liu, C. G., Kafri, T., Razin, A., Cedar, H., and Barlow, D. P. (1993). Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. *Cell* **73**, 61–71.
79. Wutz, A., Smrzka, O. W., Schweifer, N., Schellander, K., Wagner, E. F., and Barlow, D. P. (1997). Imprinted expression of the Igf2r gene depends on an intronic CpG island. *Nature* **389**, 745–749.
80. Birger, Y., Shemer, R., Perk, J., and Razin, A. (1999). The imprinting box of the mouse Igf2r gene. *Nature* **397**, 84–88.
81. Smrzka, O. W., Fae, I., Stöger, R., Kurzbauer, R., Fischer, G. F., Henn, T., Weith, A., and Barlow, D. P. (1995). Conservation of a maternal-specific methylation signal at the human IGF2R locus. *Hum. Mol. Genet.* **4**, 1945–1952.
82. Rieswijk, A. M., Schepens, M. T., Welch, T. R., Van den Berg-Loonen, E. M., Mariman, E. M., Ropers, H. H., and Kalscheuer, V. M. (1996). Maternal-specific methylation of the human *IGF2R* gene is not accompanied by allele-specific transcription. *Genomics* **31**, 158–166.
83. Chappell, S. A., Walsh, T., Walker, R. A., and Shaw, J. A. (1997). Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. *Br. J. Cancer* **76**, 1558–1561.

Received March 3, 1999

# Review

## Genomic Imprinting: Implications for Human Disease

J. Greg Falls,\* David J. Pulford,\*<sup>†</sup>  
Andrew A. Wylie,\*<sup>†</sup> and Randy L. Jirtle\*

From the Department of Radiation Oncology,\* Duke University Medical Center, Durham, North Carolina, and Department of Safety of Medicines,<sup>†</sup> Zeneca Pharmaceuticals, Ltd., Cheshire, United Kingdom

**Genomic imprinting refers to an epigenetic marking of genes that results in monoallelic expression. This parent-of-origin dependent phenomenon is a notable exception to the laws of Mendelian genetics. Imprinted genes are intricately involved in fetal and behavioral development. Consequently, abnormal expression of these genes results in numerous human genetic disorders including carcinogenesis. This paper reviews genomic imprinting and its role in human disease. Additional information about imprinted genes can be found on the Genomic Imprinting Website at <http://www.geneimprint.com>. (*Am J Pathol* 1999, 154:635-647)**

Genomic imprinting (also referred to as gametic or parental imprinting) is the epigenetic marking of a gene based on its parental origin that results in monoallelic expression. Genomic imprinting differs from classical genetics in the sense that the parental complement of imprinted genes are not equivalent with respect to their expression, despite both parents contributing equally to the genetic content of their progeny. The mechanism of imprinting is complex and not completely understood; however, evidence suggests that the "imprint mark" is a parental-specific methylation of CpG-rich domains that is established during gametogenesis. The imprint marks on a gene must be erasable in the germline when transmitted through individuals of the opposite sex, but maintained during somatic cell division (Figure 1).

The total number of publications on genomic imprinting has increased markedly over the past 10 years and has now reached almost 1500 (Figure 2). There are now more than 25 identified imprinted genes (Table 1), and estimates based on mouse models indicate that as many as 100 to 200 may exist.<sup>1</sup> Imprinted genes are involved in many aspects of development including fetal and placental growth, cell proliferation, and adult behavior. Conse-

quently, alteration of normal imprinting patterns gives rise to numerous human genetic diseases including cancer. This review examines the role of genomic imprinting in several human genetic diseases such as the Beckwith-Wiedemann, Prader-Willi, and Angelman syndromes, as well as the evidence implicating genomic imprinting in behavioral disorders and carcinogenesis. For excellent reviews on the mechanistic models of genomic imprinting, consult Reik and Walter,<sup>2</sup> Constancia et al<sup>3</sup>, and Barlow.<sup>4</sup>

### Background


Genomic imprinting plays a critical role in embryogenesis as evidenced by certain aberrations of human pregnancy. The complete hydatidiform mole arises from the fertilization of an anuclear egg either by a haploid sperm (followed by duplication of the paternal genome) or two haploid sperm (diandric diploidy).<sup>5</sup> This trophoblastic disease is characterized by a completely androgenetic (Ag) genome and results in reduced or absent fetal growth coupled with hyperplastic extraembryonic growth.<sup>6,7</sup> In contrast, ovarian dermoid cysts arise from the spontaneous activation of an ovarian oocyte resulting in the duplication of the maternal genome.<sup>8</sup> These abnormalities indicate that normal human development proceeds only when a complete complement of the paternal and maternal genomes is present.

Experimental evidence for the requirement of both the maternal and paternal chromosomal complements was demonstrated through the manipulation of mouse embryos.<sup>9,10</sup> Mouse embryos were altered *in vitro* to produce diploid Ag or diploid parthenogenetic (Pg) embryos, possessing only paternal or maternal chromosomes, respectively. Similarities to the human pregnancy aberrations were apparent since Ag mouse embryos had reduced fetal growth and proliferative extraembryonic growth while Pg embryos maintained relatively normal fetal growth but exhibited poor extraembryonic growth. Nei-

Supported by National Institutes of Health grants CA25951 and ES08823, Department of Defense Grant DAMD17-98-1-8305 (to J.G.F. and R.L.J.), and Zeneca Pharmaceuticals (to D.J.P. and A.A.W.).


Accepted for publication January 6, 1999.

Address reprint requests to Randy L. Jirtle, Box 3433, Duke University Medical Center, Durham, NC 27710. E-mail: [jirtle@radonc.duke.edu](mailto:jirtle@radonc.duke.edu).



**Figure 1.** Imprint establishment and propagation during gametogenesis and development. The paternal allele (dashed line) is imprinted and the maternal allele is expressed (solid line). The "imprint mark" (black box) represents a parental-specific methylation established during gametogenesis. **A:** The maternal and paternal genomes have different imprint patterns following fertilization. **B:** Both "imprint marks" and imprint reading are maintained during somatic cell division. **C:** The parental specific imprints are erased in the primordial germ cells. **D:** The appropriate "imprint marks" are reestablished for the next generation.

ther Ag nor Pg embryos were viable to term.<sup>9,10</sup> This demonstrates that genes expressed exclusively from one parental genome exist, and abnormal embryonic development results from the loss of function of these mono-allelically expressed genes. A mark or imprint conferring parental memory must therefore differentiate between the parental genomes, be present on the parental chromosomes through cell division, and be inheritable. This was confirmed when nuclei from early haploid preimplantation embryos were transplanted into fertilized eggs following the removal of one pronucleus. The embryo was viable only if the sex of the donor nucleus was opposite that of the remaining pronucleus.<sup>11</sup>



**Figure 2.** Total number of papers published on genomic imprinting versus time.

The chromosomal regions responsible for the genomic imprinting effects observed in mouse embryos were mapped to specific mouse chromosomes by artificially generating uniparental disomies (UPD) in mice. Certain regions of distinct chromosomes were responsible for markedly different phenotypes ranging from embryonic lethality to various growth and developmental defects apparent only after birth. These effects were dependent on whether the two copies were inherited entirely from one parent, resulting in either duplication or deficiency of genes in these chromosomal regions.<sup>12-14</sup> It was initially postulated that only mouse chromosomes 2, 6, 7, 11, 12, and 17 harbored imprinted chromosomal regions.<sup>15</sup> However, there are now reports of other chromosomes either containing more localized areas of genomic imprinting or harboring genes that show more subtle imprinted effects.

UPD also results in phenotypic abnormalities in humans. These include maternal UPD for chromosomes 2, 7, 14, 15, and 16, and paternal UPD for chromosomes 6, 11, 14, 15, and 20.<sup>16</sup> Classic examples of diseases associated with regional maternal and paternal UPD on chromosome 15 include the Prader-Willi syndrome and Angelman syndrome, respectively. Investigations of these genetic diseases are now helping to elucidate the mechanisms of genomic imprinting in humans.

### Imprinting of Specific Genes

The first endogenous imprinted gene identified was mouse insulin-like growth factor 2 (*Igf2*), which encodes for a critical fetal-specific growth factor. A targeted mutation in *Igf2* gave rise to a heterozygous dwarfing phenotype when the mutation was passed from the father while the offspring were normal when the mutation was inherited from the mother.<sup>17</sup> Furthermore, the dwarfing phenotype was observed in paternal heterozygotes and homozygotes suggesting that *Igf2* gene expression is exclusively from the paternal allele. At about the same time, the mannose 6-phosphate/insulin-like growth factor type 2 receptor (*M6p/Igf2r*) gene was shown to be imprinted and maternally expressed in mice.<sup>18</sup> Interestingly, the products of these oppositely imprinted genes interact at the biochemical level since the degradation of *Igf2* occurs via the *M6p/Igf2r*.<sup>19</sup> When a mutation was targeted to the *M6p/Igf2r* in mice, maternal heterozygotes or homozygotes showed a 30% increase in fetal growth, but they were not viable at birth.<sup>20</sup> Thus, the reciprocally imprinted *Igf2* and *M6p/Igf2r* genes both play an important role in regulating embryonic development and fetal growth.<sup>17,20</sup>

Numerous techniques have now been used to identify additional imprinted genes. Positional cloning coupled with candidate gene testing has identified novel human imprinted genes located in imprinted clusters at chromosome positions 11p15.5 and 15q11-q13. Techniques have also used parental differences in DNA methylation and expression to identify imprinted genes. Subtractive hybridization or differential display using cDNA from Pg, Ag, and fertilized embryos have yielded novel imprinted

Table 1. Identified Imprinted Genes and Transcripts

Human			Mouse			References
Gene	Location	Expressed allele	Gene	Location	Expressed allele	
<i>NOEY2 (ARHI)</i>	1p31	Paternal				129
<i>p73</i>	1p36	Maternal				147, 148
<i>U2AFBPL</i>	5q22-q31	Biallelic	<i>U2afbp-rs</i>	Proximal 11	Paternal	25, 149, 150
<i>MAS1</i>	6q25.3-q26	Biallelic/ Monoallelic in breast	<i>Mas</i>	Proximal 17	Paternal	151-153
<i>M6P/IGF2R</i>	6q26-q27	Biallelic/ Maternal*	<i>M6p/Igf2r</i>	Proximal 17	Maternal	18, 136-139
			<i>Igf2r-AS</i>	Proximal 17	Paternal	4, 140
<i>GRB10</i>	7p11.2-12	NR	<i>Meg1/Grb10</i>	Proximal 11	Maternal	31
<i>PEG1/MEST</i>	7q32	Paternal	<i>Peg1/Mest</i>	Proximal 6	Paternal	21, 154, 155
<i>WT1</i>	11p13	Biallelic/ Maternal*	<i>Wt1</i>	2	NR	120, 156
<i>ASCL2/HASH2</i>	11p15.5	Maternal	<i>Mash2</i>	Distal 7	Maternal	157, 158
<i>H19</i>	11p15.5	Maternal	<i>H19</i>	Distal 7	Maternal	30, 159
<i>IGF2</i>	11p15.5	Paternal	<i>Igf2</i>	Distal 7	Maternal	17, 36, 160-162
			<i>Igf2-AS</i>	Distal 7	Paternal	36
<i>IMPT1/BWR1A/ ORCTL2/TSSC5</i>	11p15.5	Maternal	<i>Impt1</i>	Distal 7	Maternal	163-166
<i>INS</i>	11p15.5	Biallelic	<i>Ins2</i>	Distal 7	Paternal	167-169
<i>IPL/TSSC3/BWR1C</i>	11p15.5	Maternal	<i>Ipl</i>	Distal 7	Maternal	164, 170, 171
<i>ITM</i>	11p15.5	NR	<i>Itm</i>	Distal 7	Maternal	172
<i>KvLQT1</i>	11p15.5	Maternal	<i>Kvlqt1</i>	Distal 7	Maternal	62, 173
<i>p57<sup>KIP2</sup>/CDKN1C</i>	11p15.5	Maternal	<i>p57<sup>KIP2</sup></i>	Distal 7	Maternal	48, 122, 174
<i>TAPA1</i>	11p15.5	Biallelic†	<i>Tapa1</i>	Distal 7	Maternal?	27, 67, 104
<i>HTR2A</i>	13q14	Biallelic/ Maternal*	<i>Htr2</i>	14,Band D3	Maternal	145, 175, 176
<i>FNZ127</i>	15q11-q13	Paternal				177
<i>GABRA5</i>	15q11-q13	Paternal?†	<i>Gabra5</i>	Central 7	Biallelic	26, 27, 178
<i>GABRB3</i>	15q11-q13	Paternal?†	<i>Gabrb3</i>	Central 7	Biallelic	26, 27, 179
<i>GABRG3</i>	15q11-q13	Paternal?†	<i>Gabrg3</i>	Central 7	Biallelic	26, 27, 178
<i>IPW</i>	15q11-q13	Paternal	<i>Ipw</i>	Central 7	Paternal	35, 177, 180, 181
<i>NDN (necdin)</i>	15q11-q13	Paternal	<i>Ndn</i>	Central 7	Paternal	82, 181, 182
<i>PAR1</i>	15q11-q13	Paternal				177, 180
<i>PAR5</i>	15q11-q13	Paternal				177, 180
<i>PAR-SN</i>	15q11-q13	Paternal				183
<i>SNRPN</i>	15q11-q13	Paternal	<i>Snrpn</i>	Central 7	Paternal	84, 184-186
<i>UBE3A</i>	15q11-q13	Maternal	<i>Ube3a</i>	Central 7	Maternal	77-79
<i>ZNF127</i>	15q11-q13	Paternal	<i>Zfp127</i>	Central 7	Paternal	80, 181, 187
<i>PEG3</i>	19q13.4	Paternal	<i>Peg3/Apoc2</i>	Proximal 7	Paternal	22, 188
<i>Neuronatin</i>	20q11.2-q12	NR	<i>Peg5/Nnat</i>	Distal 2	Paternal	23, 189, 190
<i>GNAS1</i>	20q13	Paternal	<i>Gnas1</i>	Distal 2	Maternal/ Paternal	191-194
<i>XIST</i>	Xq13.2 (XIC)†	Paternal?	<i>Xist</i>	Xic	Paternal	195-200
			<i>Grf1/Cdc25<sup>Mm</sup></i>	Distal 9	Paternal	24
			<i>Impact</i>	Proximal 18	Paternal	201
			<i>Ins1</i>	Distal 19	Paternal	167, 202

NR, not reported.

\* Polymorphic imprinting.

† Determined *in vitro*.

‡ X-inactivation center.

genes such as *Peg1/Mest*, a mesoderm restricted hydro-lase at mouse chromosome 6; *Peg3*, a novel zinc-finger protein on proximal mouse chromosome 7; and *Peg5/Nnat* located on mouse chromosome 2.<sup>21-23</sup> The *Grf1* and *U2af1-rs1* imprinted genes were identified by a genome-wide screen termed restriction landmark genome screening (RLGS).<sup>24,25</sup> Finally, three GABAA receptor subunit genes (*GABRB3*, *GABRA5*, and *GABRG3*) were shown to be exclusively expressed from the paternal allele by microcell-mediated chromosome transfer.<sup>26</sup> More recently,

results from a somatic-cell hybrid system indicated that these receptor subunit genes were not imprinted.<sup>27</sup>

### Characteristics of Imprinted Genes

Several theories have been proposed for the endogenous function of genomic imprinting. Moore and Haig<sup>28</sup> have suggested that genomic imprinting in mammals has evolved from a conflict of interest between the paternal and maternal genome in regulating fetal growth. Whereas

benefits of a large placenta and fetus might ensure future propagation of a paternal line, the result may tax the resources of the mother, thereby compromising future pregnancies. Conversely, if fetal and placental growth is held in check, more offspring from the mother's (and possibly different father's) lineage may be produced. Accordingly, the mother would be predicted to imprint or silence genes that promote placental and fetal growth, whereas the father would imprint genes that inhibit growth.

In support of this theory, the gene encoding the fetal growth factor, *Igf2*, is maternally imprinted, whereas *H19*, which encodes for an untranslated RNA involved in silencing *Igf2* expression, is paternally imprinted.<sup>17,29,30</sup> The result of this reciprocal imprinting is parent-of-origin, monoallelic paternal expression of the gene encoding for *Igf2*. Interestingly, the genes that encode for the *M6p/Igf2r* which degrades *Igf2*, and *Meg1/Grb10* which inhibits *Igf2* signaling are both paternally imprinted, adding further support for this theory.<sup>18,19,31</sup>

An alternative proposal for imprinting suggests that the cytosine methylation involved in imprint regulation evolved as a defense mechanism for the inactivation of parasitic sequences such as transposable elements and proviral DNA.<sup>32</sup> This is supported by the finding that 5-aza-deoxycytidine, an inhibitor of cytosine DNA methyltransferase, activates silent retroviruses.<sup>33</sup> Irrespective of the reason for the evolution of genomic imprinting in mammals, the functional consequences of genomic imprinting include the inhibition of parthenogenesis and the loss of protection from deleterious recessive mutations.

As more imprinted genes are identified, the characteristics of imprinting are becoming apparent. For example, two chromosomal regions harbor more than one imprinted gene. These imprinting clusters reside at human chromosome 11p15.5 (syntenic to the distal region of mouse chromosome 7) and human chromosome 15q11-q13 (syntenic to the central region of mouse chromosome 7). Within these imprinted gene clusters, genes have been identified that encode for untranslated RNA<sup>34,35</sup> and antisense RNA<sup>36,37</sup> that may be involved in imprint control. Some imprinted genes, such as *H19* and *IGF2*, that are located in imprinted clusters show coordinate regulation. Imprinted genes also often reside in chromosomal regions that undergo asynchronous replication,<sup>38,39</sup> and the meiotic recombination frequencies in these regions may differ between the male and female germ cells.<sup>40</sup> Another characteristic of imprinted genes is an associated allele-specific DNA methylation of cytosine residues in CpG dinucleotides that appears to distinguish the parental alleles.<sup>41-43</sup> Repetitive elements associated with the areas of differential methylation have also been identified in several imprinted genes (ie, *H19*, *M6p/Igf2r*, *U2afp-rs*, and *p57<sup>KIP2</sup>*).<sup>44-48</sup>

## Imprinting in Genetic Diseases

### Beckwith-Wiedemann Syndrome

There are a number of human genetic diseases associated with imprinting defects (reviewed in Refs. 49 and

50). Beckwith-Wiedemann syndrome (BWS) maps to 11p15 and is characterized by general overgrowth with symptoms including hemihypertrophy, macroglossia, and visceromegaly. Genomic imprinting in BWS was first suspected when preferential maternal transmission of mutations was observed in some BWS families.<sup>51</sup> Additionally, approximately 10-20% of BWS individuals are predisposed to embryonal tumors, the most frequent of which are Wilms' tumors and adrenocortical carcinoma.<sup>52</sup> The rate of Wilms' tumor formation in the BWS population is 1000-fold higher than in the normal population, and these tumors often show preferential loss of maternal 11p15.<sup>53</sup> The majority of BWS cases arise sporadically; however, in both sporadic and familial forms, a small percentage exhibits UPD at chromosome 11p15. In these cases, the remainder of the chromosome is biparental in inheritance, indicative of somatic mosaicism through a postfertilization mitotic recombination event.<sup>54,55</sup>

The most common molecular event occurring in BWS patients that do not have cytogenetic abnormalities is the biallelic expression of *IGF2* due to loss of imprinting (LOI).<sup>56,57</sup> LOI at the *IGF2* locus may be accompanied by the methylation and/or silencing of the active maternal allele of *H19*.<sup>58,59</sup> This *H19*-dependent event is consistent with an enhancer-competition model for the co-regulation of these genes.<sup>60</sup>

Translocations in BWS patients may also lead to LOI at the *IGF2* locus, but without loss of *H19* imprinting.<sup>61</sup> These translocations affect imprinting by disrupting a gene involved in imprint control, or by altering the function of an imprinting center (IC). Therefore, disruption of *IGF2* imprinting in BWS may also occur via an *H19*-independent event.<sup>56,57</sup> The imprinted *KvLQT1* gene located centromeric to *IGF2* spans a common breakpoint region in BWS, and has been proposed to maintain regional imprint control at 11p15.5.<sup>60</sup> *KvLQT1* shows preferential expression from the maternal allele in most tissues examined except the heart where it is biallelically expressed.<sup>62</sup> This explains why *KvLQT1*, responsible for the autosomal dominant cardiac arrhythmia long QT syndrome, shows no parent-of-origin effect in this disorder. The maternally expressed *p57<sup>KIP2</sup>*, which encodes for a cyclin-dependent kinase inhibitor, also maps to 11p15.5. Abnormal imprinting and epigenetic silencing of *p57<sup>KIP2</sup>* is found in some individuals with BWS,<sup>63</sup> and mutations are present in about 5% of BWS patients.<sup>64-66</sup>

To date, ten imprinted genes have been mapped to 11p15.5 (Table 1). Flanking these imprinted genes are the non-imprinted *NAP2* (centromeric border) and *L23MRP* (telomeric border) genes.<sup>67</sup> The syntenic region in the mouse, distal chromosome 7, confirms the existence of an imprinting cluster at this chromosomal location.<sup>68</sup> A possible explanation for the involvement of multiple genes in BWS (even if *IGF2* overexpression is directly responsible for BWS) is that one or more of the adjacent genes (eg, *H19*, *p57<sup>KIP2</sup>*, *KvLQT1*) are involved in the regulation of *IGF2* expression. Experimental evidence supports this postulate since transgenic mice that overexpress *Igf2* develop symptoms similar to BWS.<sup>69</sup>

## Prader-Willi and Angelman Syndromes

Two clinically distinct genetic diseases associated with genomic imprinting on chromosome 15q11-q13 are the Prader-Willi syndrome (PWS) and the Angelman syndrome (AS). Each syndrome is associated with deficiencies in sexual development and growth, and behavioral and mental problems including retardation.<sup>70,71</sup> Major diagnostic criteria for PWS patients include hypotonia, hyperphagia and obesity, hypogonadism and developmental delay.<sup>72</sup> AS patients often display ataxia, tremulousness, sleep disorders, seizures, and hyperactivity. Severe mental retardation accompanied with a lack of speech may also be present, but AS individuals often display a happy disposition with outbreaks of laughter.<sup>73</sup>

PWS and AS are autosomal dominant disorders showing parent-of-origin effects since the inherited diseases are transmitted from only one of the parents. Approximately 70% of PWS and AS individuals have a *de novo* 3- to 4-megabase deletion in their paternal or maternal chromosome 15q11-q13, respectively. Maternal UPD occurs in most of the remaining PWS patients (25%); however, paternal UPD only occurs in about 4% of AS patients.<sup>16,74</sup> The preferential loss of parental alleles associated with different phenotypes, coupled with the instances of UPD indicate the involvement of imprinted genes (ie, paternally expressed gene(s) for PWS and maternally expressed gene(s) for AS).<sup>70</sup> Recently, approximately 20% of the AS patients without a chromosomal deletion were found to have truncating mutations in *UBE3A*, a gene encoding a ubiquitin protein ligase involved in protein turnover.<sup>75,76</sup> *UBE3A*, mapped to 15q11-q13, has now been reported to be maternally expressed in the human brain.<sup>77,78</sup> Thus, abnormalities in the maternal-specific expression of *UBE3A* during brain development has been proposed for AS.<sup>79</sup> This region also harbors four imprinted, paternally expressed candidate PWS genes: small nuclear riboprotein-associated polypeptide N (*SNRPN*), Imprinted in Prader-Willi (*IPW*), zinc finger 127 (*ZNF127*), and necdin (*NDN*).<sup>35,80-82</sup> The imprinted, paternally expressed transcripts of *PAR1*, *PAR5*, and *PAR-SN* may also be involved in PWS.

Imprinting defects resulting from microdeletions targeted to the *SNRPN* gene have been identified in a small percentage of PWS patients that maintain both parental complements of 15q11-q13.<sup>80,83,84</sup> These deletions alter *SNRPN* promoter methylation and prevent expression of its paternal allele. This results in the silencing of other paternally expressed genes in the cluster.<sup>83,85</sup> These microdeletions apparently disrupt an imprinting center<sup>85</sup> involved in resetting the correct imprinting pattern during gametogenesis.<sup>84,85</sup> The alternate use of *SNRPN* transcripts (BD exons) may be involved in the normal imprinting process.<sup>86</sup> Offspring inheriting microdeletions from their mother exhibit no apparent phenotype; however, a subsequent paternal transmission results in PWS. In comparison, a small percentage of AS patients have similar microdeletions in the *SNRPN* gene (albeit in a region farther upstream) that disrupt the resetting of the imprinting pattern. In this case, progeny inheriting paternal microdeletions do not develop AS, but maternal transmis-

sion to offspring results in AS. These PWS and AS microdeletion results support the IC hypothesis, but a bipartite structure must be present since the minimally deleted regions responsible for PWS and AS are distinct.<sup>87</sup> An alternate mechanism for imprinting maintenance in this region relies on an enhancer-competition model between *cis*-linked genes;<sup>4,88</sup> however, methylation analysis of the PWS/AS region reported by Schumacher et al<sup>89</sup> does not support this.

## Imprinting in Brain and Behavior Development

The paternally expressed human *MEST* gene maps to 7q32, a region where maternal UPD is associated with intrauterine and postnatal growth retardation.<sup>21,90</sup> Recently, a targeted deletion was introduced into the coding sequence of the mouse *Mest* gene to determine its function.<sup>91</sup> When the deletion was paternally derived, *Mest* +/- mice were viable and fertile; however, they exhibited growth retardation and increased lethality. *Mest* -/+ animals (deletion maternally derived) showed none of these effects indicating that the phenotypic consequences of this mutation are detected only through paternal inheritance. Interestingly, Lefebvre et al<sup>91</sup> found decreased reproductive fitness in the females that inherited the targeted disruption from their father. This effect was not based on the genotype of the progeny, but rather was due to an abnormal nurturing behavior of the mutant parturient females. Aberrant behavior of the mothers included failure to ingest the extraembryonic tissues (a normal behavior in most mammals), reduced rate of nest building, and pup neglecting. When the pups were fostered to wild-type females, no phenotypic differences between wild-type pups and *Mest* -/+ pups were apparent.

The results of this study demonstrate that the paternally expressed *Mest* is a positive regulator of embryonic growth, and is involved in the regulation of mammalian behavior associated with the rearing of offspring. These findings are consistent with the hypothesis that the imprinting of genes arises from the conflict of interest of the parental genomes in mammals,<sup>28</sup> and supports the importance of imprinted genes in brain development. Previous results using Pg and Ag mouse embryos suggested that both maternally and paternally derived genes contribute to the growth and function of specific brain regions in a complementary fashion.<sup>92</sup> Keverne et al<sup>93</sup> found that Ag cells primarily contributed to hypothalamic composition, whereas Pg cells localized to the cortex, striatum, and hippocampus, but not to the hypothalamus. Brain growth was enhanced by Pg cells and retarded by Ag cells, further supporting the postulate that genomic imprinting is critically involved in mammalian brain development.

Evidence for imprinting effects in human diseases associated with mental abnormalities includes the aforementioned Prader-Willi and Angelman syndromes. There is now also evidence of cognitive imprinting effects in humans displaying normal intelligence. Skuse et al<sup>94</sup> recently reported that an imprinted X-linked locus is poten-


tially responsible for differences in cognitive function of females with Turner's syndrome. Although normal females (46,XX) inherit an X chromosome from both their mother and father, only one X chromosome is inactivated. Turner's syndrome is a sporadic disorder resulting when all or part of one X chromosome is deleted in females. These females display normal intelligence, but overall have a higher incidence of social difficulties.<sup>95,96</sup> Turner syndrome women who inherit the X chromosome from their mother (45,Xm) generally exhibit more behavioral difficulties than those inheriting the X chromosome from their father (45,Xp). This finding provides the first evidence of genomic imprinting on the human X chromosome.<sup>94</sup> Based on cytogenetic analysis of these patients, partial deletions of the short arm of the paternally derived X chromosome were found. This suggests that the putative imprinted locus escapes X-inactivation and potentially lies in Xp11.23-Xqter. Interestingly, Miller and Willard<sup>97</sup> have recently identified a 5.5 megabase region on the human Xp11.21-p11.22 that contains eight expressed sequences which escape X inactivation. However, an imprinted gene(s) in this region is yet to be identified.

Parent-of-origin effects involved in other behavioral and brain disorders have also been reported. Included among these are bipolar affective disorder,<sup>98-100</sup> schizophrenia,<sup>101,102</sup> and autism.<sup>103</sup> However, the involvement of genomic imprinting in these examples remains to be elucidated. For an extensive summary of parent-of-origin effects in human disease, consult Morison and Reeve.<sup>104</sup>

### Imprinting in Human Cancer

There are numerous reports of tumors showing a bias in allelic loss. On a genome-wide scale, the complete hydatidiform mole and benign ovarian dermoid cyst arise from cells that are completely Ag or Pg in origin, respectively.<sup>105,106</sup> In addition, numerous tumors are associated with the preferential loss of a particular parental chromosome, indicating the involvement of imprinted genes. Examples include neuroblastoma (maternal chromosome 1p36 and paternal chromosome 2),<sup>107</sup> acute myeloblastic leukemia (paternal chromosome 7),<sup>108</sup> Wilms' tumor (maternal chromosome 11p15.5),<sup>109</sup> rhabdomyosarcoma (maternal chromosome 11p15.5),<sup>110</sup> and sporadic osteosarcoma (maternal chromosome 13).<sup>111</sup> A role for genomic imprinting has also been implicated in the development of familial glomus tumors based on inheritance patterns since tumor susceptibility is inherited paternally.<sup>112</sup>

Imprinted genes can be involved in carcinogenesis in several ways (Figure 3). Loss of heterozygosity or UPD at an imprinted region may result in the deletion of the only functional copy of a tumor suppressor gene. Alternatively, LOI or UPD of an imprinted gene that promoted cell growth may allow gene expression to be inappropriately increased. Finally, mutational inactivation of an IC might result in the aberrant expression of multiple imprinted oncogenes and/or tumor suppressor genes present in an imprinted chromosomal region.



**Figure 3.** A: Only one allele of a tumor suppressor gene (T) is expressed because of genomic imprinting (T<sup>S</sup>). Loss of heterozygosity (LOH) of the expressed allele or an inactivating mutation in the expressed allele (T<sup>M</sup>) results in loss of tumor suppressor function. B: Only one allele of the proto-oncogene (P) is expressed because of genomic imprinting (P<sup>S</sup>). Loss of imprinting (LOI) or uniparental disomy (UPD) results in biallelic expression of the proto-oncogene.

Aberrant genomic imprinting and its role in cancer are best exemplified by studies on Wilms' tumor, a childhood tumor that arises from metanephric blastemal cells. Direct genetic evidence linking tumorigenesis and aberrant imprinting was identified when 70% of Wilms' tumors were found to have biallelic *IGF2* expression.<sup>113-115</sup> Inactivation of *H19* was also present in a number of these cases.<sup>115</sup> The *H19* gene possesses a CpG island in its promoter that is normally methylated on the paternal allele and unmethylated on the maternal allele.<sup>44,45,115</sup> An enhancer competition model for the reciprocal control of expression of the imprinted *IGF2* and *H19* genes has recently been proposed.<sup>116,117</sup> Thus, LOI of the *IGF2* gene in Wilms' tumor could result from loss of *H19* expression.<sup>116,117</sup> This scenario is supported by the finding that *H19* null transgenic mice show biallelic expression of *IGF2*.<sup>118</sup> The coupling of biallelic *IGF2* gene expression with *H19* inactivation is even observed in phenotypically normal kidney tissue surrounding the Wilms' tumor. This suggests that the inactivation of *H19* and the biallelic expression of *IGF2* are linked, and occur early in development.<sup>119</sup> Other human malignancies showing LOI at the *IGF2* locus are presented in Table 2. These results indicate deregulation of *IGF2* imprinting is mechanistically involved in the development of a variety of tumors.

Because imprinted genes are functionally haploid, an imprinted tumor suppressor gene would be predicted to increase cancer susceptibility since the inactivation of only one allele would eliminate tumor suppressor function. *WT1*,<sup>120,121</sup> *p57<sup>KIP2</sup>*,<sup>122-124</sup> and *M6P/IGF2R*<sup>125-128</sup> represent imprinted genes implicated in tumor suppression. *p57<sup>KIP2</sup>*, mapped to 11p15.5, encodes for a cyclin-dependent kinase inhibitor that is maternally expressed. Epigenetic silencing of the expressed allele has been reported in some tumors and BWS patients.<sup>63</sup> Additionally, approximately 5% of BWS patients have *p57<sup>KIP2</sup>*

Table 2. Aberrant Imprinting in Human Cancer

Tumor type	Gene	Reference
<i>Childhood Tumors</i>		
Wilms' tumor	<i>IGF2, H19, p57<sup>KIP2</sup>, M6P/IGF2R</i>	63, 113, 139, 162
Rhabdomyosarcoma	<i>IGF2</i>	203
Ewing's sarcoma	<i>IGF2</i>	204
Hepatoblastoma	<i>IGF2</i>	205, 206
<i>Adult Tumors</i>		
Bladder	<i>IGF2, H19, IPW</i>	207, 208
Breast	<i>IGF2</i>	209, 210
Cervical	<i>IGF2, H19</i>	211
Choriocarcinoma	<i>IGF2, H19</i>	212
Colorectal	<i>IGF2</i>	213
Esophageal	<i>H19</i>	214
Gastric adenocarcinoma	<i>IGF2</i>	215
Glioma	<i>IGF2</i>	216
Hepatocellular	<i>IGF2, H19</i>	217, 218
Leukemia-acute myeloid	<i>IGF2</i>	219
Leukemia-chronic myelogenous	<i>IGF2</i>	220
Lung	<i>IGF2, H19, p73</i>	221-223
Medulloblastoma	<i>IGF2, H19</i>	224
Mesothelioma	<i>IGF2</i>	225
Ovarian	<i>IGF2</i>	226
Prostate	<i>IGF2</i>	227
Renal cell carcinoma	<i>IGF2, p73</i>	148, 228
Testicular germ cell	<i>IGF2, H19</i>	229
Uterine	<i>IGF2</i>	230

mutations,<sup>64</sup> however, *p57<sup>KIP2</sup>* mutations have not been identified in tumors. Thus, the putative tumor suppressor function of *p57<sup>KIP2</sup>* remains to be clarified. Recently, *NOEY2 (ARHI)*, a novel *ras*-related, maternally imprinted gene at 1p31, was identified as a putative tumor suppressor gene in breast and ovarian carcinomas. In the majority of cases, the functional allele was lost.<sup>129</sup>

Recent reports demonstrate that the *M6P/IGF2R* at 6q26 is inactivated in a variety of tumors at the earliest stage of transformation.<sup>126-128</sup> The *M6P/IGF2R* plays an integral part in the intracellular sorting of lysosomal enzymes, the activation of the growth inhibitor transforming growth factor- $\beta$ 1 (*TGF- $\beta$ 1*), and the degradation of *IGF2*, but it is not directly involved in cell signaling.<sup>19,130</sup> The *M6P/IGF2R* is mutated in 60% of dysplastic liver lesions and hepatocellular carcinomas of patients with or without hepatitis virus infection.<sup>125,126,128</sup> The *M6P/IGF2R* is also mutated in 30% of breast tumors,<sup>127</sup> and the gene contains a polyG region that is a common mutational target in colon, gastric and endometrial tumors with mismatch repair deficiencies and microsatellite instability.<sup>128,131,132</sup> Moreover, it has recently been reported that the *M6P/IGF2R* is mutated in human glioma samples that do not contain mutations in the transforming growth factor- $\beta$  type II receptor (*TGFBRII*) or *Bax* genes.<sup>133</sup> In both breast<sup>127,134</sup> and liver carcinogenesis,<sup>128</sup> the allelic inactivation of *M6P/IGF2R* occurs as an early event, during the initiation rather than the progression stage of transformation.

Although imprinting among individuals and mammalian species is generally conserved, the imprint status of *M6P/IGF2R* in humans and rodents is strikingly different. The *M6p/Igf2r* is imprinted in mice<sup>18</sup> and rats,<sup>135</sup> but imprinting at this locus appears to be a polymorphic trait

in humans, with most individuals having biallelic expression.<sup>136-138</sup> The existence of individuals with an imprinted *M6P/IGF2R* tumor suppressor suggests that they may have increased susceptibility to tumor development because of aberrant imprint control. This postulate is supported by Xu et al<sup>139</sup> who recently reported partial imprinting of *M6P/IGF2R* in 50% of Wilms' tumor patients.

The precise molecular mechanism for genomic imprinting of *M6P/IGF2R* is not completely defined. Methylation of a CpG rich region in intron 2 (Region 2) of the expressed maternal allele has been shown to carry the imprint signal for this gene in mice.<sup>46,140</sup> Birger et al<sup>141</sup> have identified a 113-bp sequence, in region 2 of the mouse *M6p/Igf2r* gene, that serves as a methylation imprinting box responsible for the establishment of differential methylation. Furthermore, this region appears to function as the promoter of an antisense transcript that originates only from the repressed paternal allele. This indicates that a form of expression competition regulates imprinting of the *M6p/Igf2r* gene in mice.<sup>140</sup> Region 2 of the human *M6P/IGF2R* also contains parent-of-origin methylation, but gene expression is biallelic.<sup>142,143</sup> Consequently, humans and mice appear to possess an altered ability to read the *M6P/IGF2R* imprint marks.

Functional polymorphic imprinting has also been observed for human genes encoding *IGF2*,<sup>144</sup> *WT1*,<sup>120</sup> and the human 5-HT<sub>2A</sub> receptor gene *HTR2A*.<sup>145</sup> Recently, the mouse *Kvlqt1* gene has been shown to undergo developmental relaxation of imprinting in a strain-dependent fashion.<sup>146</sup> Whether polymorphic genomic imprinting occurs in other genes, and functions in determining individual and/or species differences in susceptibility to diseases remains to be determined.

## References

- Barlow DP: Gametic imprinting in mammals. *Science* 1995, 270:1610-1613
- Reik W, Walter J: Imprinting mechanisms in mammals. *Curr Opin Genet Dev* 1998, 8:154-164
- Constancia M, Pickard B, Kelsey G, Reik W: Imprinting mechanisms. *Genome Res* 1998, 8:881-900
- Barlow DP: Competition—a common motif for the imprinting mechanism? *EMBO J* 1997, 16:6899-6905
- Lindor NM, Ney JA, Gaffey TA, Jenkins RB, Thibodeau SN, Dewald GW: A genetic review of complete and partial hydatidiform moles and nonmolar triploidy. *Mayo Clin Proc* 1992, 67:791-799
- Kajii T, Ohama K: Androgenetic origin of hydatidiform mole. *Nature* 1977, 268:633-634
- Ohama K, Kajii T, Okamoto E, Fukuda Y, Imaizumi K, Tsukahara M, Kobayashi K, Hagiwara K: Dispermic origin of XY hydatidiform moles. *Nature* 1981, 292:551-552
- Ohama K, Nomura K, Okamoto E, Fukuda Y, Ihara T, Fujiwara A: Origin of immature teratoma of the ovary. *Am J Obstet Gynecol* 1985, 152:896-900
- McGrath J, Solter D: Completion of mouse embryogenesis requires both the maternal and paternal genomes. *Cell* 1984, 37:179-183
- Surani MA, Barton SC, Norris ML: Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. *Nature* 1984, 308:548-550
- Surani MA, Reik W, Norris ML, Barton SC: Influence of germline modifications of homologous chromosomes on mouse development. *J Embryol Exp Morphol* 1986, 97(Suppl):123-136
- Cattanach BM, Kirk M: Differential activity of maternally and paternally derived chromosome regions in mice. *Nature* 1985, 315:496-498
- Searle AG, Beechey CV: Complementation studies with mouse translocations. *Cytogenet Cell Genet* 1978, 20:282-303
- Searle AG, Beechey CV: Genome imprinting phenomena on mouse chromosome 7. *Genet Res* 1990, 56:237-244
- Cattanach BM, Jones J: Genetic imprinting in the mouse: implications for gene regulation. *J Inherit Metab Dis* 1994, 17:403-420
- Ledbetter DH, Engel E: Uniparental disomy in humans: development of an imprinting map and its implications for prenatal diagnosis. *Hum Mol Genet* 1995, 4:1757-1764
- DeChiara TM, Robertson EJ, Efstratiadis A: Parental imprinting of the mouse insulin-like growth factor II gene. *Cell* 1991, 64:849-859
- Barlow DP, Stöger R, Herrmann BG, Saito K, Schweifer N: The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* 1991, 349:84-87
- Kornfeld S: Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. *Annu Rev Biochem* 1992, 61:307-330
- Wang ZQ, Fung MR, Barlow DP, Wagner EF: Regulation of embryonic growth and lysosomal targeting by the imprinted *Igf2/Mpr* gene. *Nature* 1994, 372:464-467
- Kaneko-Ishino T, Kuroiwa Y, Miyoshi N, Kohda T, Suzuki R, Yokoyama M, Viville S, Barton SC, Ishino F, Surani MA: Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. *Nat Genet* 1995, 11:52-59
- Kuroiwa Y, Kaneko-Ishino T, Kagitani F, Kohda T, Li LL, Tada M, Suzuki R, Yokoyama M, Shiroishi T, Wakana S, Barton SC, Ishino F, Surani MA: Peg3 imprinted gene on proximal chromosome 7 encodes for a zinc finger protein. *Nat Genet* 1996, 12:186-190
- Kagitani F, Kuroiwa Y, Wakana S, Shiroishi T, Miyoshi N, Kobayashi S, Nishida M, Kohda T, Kaneko-Ishino T, Ishino F: Peg5/Neuronatin is an imprinted gene located on sub-distal chromosome 2 in the mouse. *Nucleic Acids Res* 1997, 25:3428-3432
- Plass C, Shibata H, Kalcheva I, Mullins L, Kotelevtseva N, Mullins J, Kato R, Sasaki H, Hirotsune S, Okazaki Y, Held WA, Hayashizaki Y, Chapman VM: Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M. *Nat Genet* 1996, 14:106-109
- Hatada I, Sugama T, Mukai T: A new imprinted gene cloned by a methylation-sensitive genome scanning method. *Nucleic Acids Res* 1993, 21:5577-5582
- Meguro M, Mitsuya K, Sui H, Shigenami K, Kugoh H, Nakao M, Oshimura M: Evidence for uniparental, paternal expression of the human GABAA receptor subunit genes, using microcell-mediated chromosome transfer. *Hum Mol Genet* 1997, 6:2127-2133
- Gabriel JM, Higgins MJ, Gebuhr TC, Shows TB, Saitoh S, Nicholls RD: A model system to study genomic imprinting of human genes. *Proc Natl Acad Sci USA* 1998, 95:14857-14862
- Moore T, Haig D: Genomic imprinting in mammalian development: a parental tug-of-war. *Trends Genet* 1991, 7:45-49
- DeChiara TM, Efstratiadis A, Robertson EJ: A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. *Nature* 1990, 345:78-80
- Bartolomei MS, Zemel S, Tilghman SM: Parental imprinting of the mouse H19 gene. *Nature* 1991, 351:153-155
- Miyoshi N, Kuroiwa Y, Kohda T, Shitara H, Yonekawa H, Kawabe T, Hasegawa H, Barton SC, Surani MA, Kaneko-Ishino T, Ishino F: Identification of the Meg1/Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene. *Proc Natl Acad Sci USA* 1998, 95:1102-1107
- Bestor TH, Tycko B: Creation of genomic methylation patterns. *Nat Genet* 1996, 12:363-367
- Jaenisch R, Schnieke A, Harbers K: Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. *Proc Natl Acad Sci USA* 1985, 82:1451-1455
- Zhang Y, Tycko B: Monoallelic expression of the human H19 gene. *Nature Genet* 1992, 1:40-44
- Wevrick R, Kerns JA, Francke U: Identification of a novel paternally expressed gene in the Prader-Willi syndrome region. *Hum Mol Genet* 1994, 3:1877-1882
- Moore T, Constancia M, Zubair M, Bailleul B, Feil R, Sasaki H, Reik W: Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse *Igf2*. *Proc Natl Acad Sci USA* 1997, 94:12509-12514
- Wutz A, Smrzka OW, Barlow DP: Making sense of imprinting the mouse and human *IGF2R* loci. *Novartis Found Symp* 1998, 214:251-259
- Knoll JH, Cheng SD, Lalande M: Allele specificity of DNA replication timing in the Angelman/Prader-Willi syndrome imprinted chromosomal region. *Nat Genet* 1994, 6:41-46
- Kitsberg D, Selig S, Brandeis M, Simon I, Keshet I, Driscoll DJ, Nicholls RD, Cedar H: Allele-specific replication timing of imprinted gene regions. *Nature* 1993, 364:459-463
- Robinson WP, Lalande M: Sex-specific meiotic recombination in the Prader-Willi/Angelman syndrome imprinted region. *Hum Mol Genet* 1995, 4:801-806
- Laird PW, Jaenisch R: The role of DNA methylation in cancer genetics and epigenetics. *Annu Rev Genet* 1996, 30:441-464
- Tycko B: DNA methylation in genomic imprinting. *Mutat Res* 1997, 386:103-105
- Razin A, Cedar H: DNA methylation and genomic imprinting. *Cell* 1994, 77:473-476
- Bartolomei MS, Webber AL, Brunkow ME, Tilghman SM: Epigenetic mechanisms underlying the imprinting of the mouse H19 gene. *Genes Dev* 1993, 7:1663-1673
- Ferguson-Smith AC, Sasaki H, Cattanach BM, Surani MA: Parental-origin-specific epigenetic modification of the mouse H19 gene. *Nature* 1993, 362:751-755
- Stöger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H, Barlow DP: Maternal-specific methylation of the imprinted mouse *Igf2r* locus identifies the expressed locus as carrying the imprinting signal. *Cell* 1993, 73:61-71
- Hatada I, Kitagawa K, Yamaoka T, Wang X, Arai Y, Hashido K, Ohishi S, Masuda J, Ogata J, Mukai T: Allele-specific methylation and expression of an imprinted *U2af1-rs1* (SP2) gene. *Nucleic Acids Res* 1995, 23:36-41
- Hatada I, Mukai T: Genomic imprinting of *p57<sup>KIP2</sup>*, cyclin-dependent kinase inhibitor, in mouse. *Nat Genet* 1995, 11:204-206
- Lalande M: Parental imprinting and human disease. *Annu Rev Genet* 1996, 30:173-195
- Hall JG: Genomic imprinting: nature and clinical relevance. *Annu Rev Med* 1997, 48:35-44
- Viljoen D, Ramesar R: Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome. *J Med Genet* 1992, 29:221-225
- Ward A: Beck-Wiedemann syndrome, and Wilms' tumour. *Mol Hum Reprod* 1997, 3:157-168

53. Feinberg AP: Genomic Imprinting: The Genetic Basis of Human Cancer. Edited by Vogelstein B, Kinzler KW. New York, McGraw-Hill Health Professions Division, 1998, pp 95-107
54. Bischoff FZ, Feldman GL, McCaskill C, Subramanian S, Hughes MR, Shaffer LG: Single cell analysis demonstrating somatic mosaicism involving 11p in a patient with paternal isodisomy and Beckwith-Wiedemann syndrome. *Hum Mol Genet* 1995, 4:395-399
55. Henry I, Puech A, Riesewijk A, Ahnine L, Mannens M, Beldjord C, Bitoun P, Tournade MF, Landrieu P, Junien C: Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a post-fertilization event. *Eur J Hum Genet* 1993, 1:19-29
56. Weksberg R, Shen DR, Fei YL, Song QL, Squire J: Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. *Nat Genet* 1993, 5:143-150
57. Joyce JA, Lam WK, Catchpoole DJ, Jenks P, Reik W, Maher ER, Schofield PN: Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. *Hum Mol Genet* 1997, 6:1543-1548
58. Reik W, Brown KW, Schneid H, Le Bouc Y, Bickmore W, Maher ER: Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. *Hum Mol Genet* 1995, 4:2379-2385
59. Catchpoole D, Lam WW, Valler D, Temple IK, Joyce JA, Reik W, Schofield PN, Maher ER: Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome. *J Med Genet* 1997, 34:353-359
60. Reik W, Maher ER: Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. *Trends Genet* 1997, 13:330-334
61. Brown KW, Villar AJ, Bickmore W, Clayton-Smith J, Catchpoole D, Maher ER, Reik W: Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. *Hum Mol Genet* 1996, 5:2027-2032
62. Lee MP, Hu RJ, Johnson LA, Feinberg AP: Human KVLQT1 gene shows tissue-specific imprinting, and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. *Nat Genet* 1997, 15:181-185
63. Thompson JS, Reese KJ, DeBaun MR, Perlman EJ, Feinberg AP: Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor. *Cancer Res* 1996, 56:5723-5727
64. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Nakayama M, Niikawa N, Mukai T: An imprinted gene p57<sup>KIP2</sup> is mutated in Beckwith-Wiedemann syndrome. *Nat Genet* 1996, 14:171-173
65. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboah K, Tycko B: Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms' tumors. *Am J Hum Genet* 1997, 61:295-303
66. Lee MP, DeBaun M, Randhawa G, Reichard BA, Elledge SJ, Feinberg AP: Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. *Am J Hum Genet* 1997, 61:304-309
67. Reid LH, Davies C, Cooper PR, Crider-Miller SJ, Sait SN, Nowak NJ, Evans G, Stanbridge EJ, deJong P, Shows TB, Weissman BE, Higgins MJ: A 1-Mb physical map, and PAC contig of the imprinted domain in 11p15.5 that contains TAPA1, and the BWSCR1/WT2 region. *Genomics* 1997, 43:366-375
68. Paulsen M, Davies KR, Bowden LM, Villar AJ, Franck O, Fuermann M, Dean WL, Moore TF, Rodrigues N, Davies KE, Hu RJ, Feinberg AP, Maher ER, Reik W, Walter J: Syntenic organization of the mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann syndrome region in chromosome 11p15.5. *Hum Mol Genet* 1998, 7:1149-1159
69. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W: Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. *Nature* 1997, 389:809-815
70. Bartolomei MS, Tilghman SM: Genomic imprinting in mammals. *Annu Rev Genet* 1997, 31:493-525
71. Nicholls RD, Saitoh S, Horsthemke B: Imprinting in Prader-Willi and Angelman syndromes. *Trends Genet* 1998, 14:194-200
72. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F: Prader-Willi syndrome: consensus diagnostic criteria. *Pediatrics* 1993, 91:398-402
73. Williams CA, Angelman H, Clayton-Smith J, Driscoll DJ, Hendrickson JE, Knoll JH, Magenis RE, Schinzel A, Wagstaff J, Whidden EM, et al: Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation. *Am J Med Genet* 1995, 56:237-238
74. Nicholls RD: Genomic imprinting and uniparental disomy in Angelman and Prader-Willi syndromes: a review. *Am J Med Genet* 1993, 46:16-25
75. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, Rommens JM, Beaudet AL: De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. *Nat Genet* 1997, 15:74-77
76. Kishino T, Lalonde M, Wagstaff J: UBE3A/E6-AP mutations cause Angelman syndrome. *Nat Genet* 1997, 15:70-73
77. Rougeulle C, Glatt H, Lalonde M: The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. *Nat Genet* 1997, 17:14-15
78. Vu TH, Hoffman AR: Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. *Nat Genet* 1997, 17:12-13
79. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, Eichele G, Beaudet AL: Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. *Nat Genet* 1997, 17:75-78
80. Glenn CC, Nicholls RD, Robinson WP, Saitoh S, Niikawa N, Schinzel A, Horsthemke B, Driscoll DJ: Modification of 15q11-q13 DNA methylation imprints in unique Angelman and Prader-Willi patients. *Hum Mol Genet* 1993, 2:1377-1382
81. Reed ML, Leff SE: Maternal imprinting of human SNRPN, a gene deleted in Prader-Willi syndrome. *Nat Genet* 1994, 6:163-167
82. Sutcliffe JS, Han M, Christian SL, Ledbetter DH: Neuronally-expressed necdin gene: an imprinted candidate gene in Prader-Willi syndrome. *Lancet* 1997, 350:1520-1521
83. Reis A, Dittich B, Greger V, Buiting K, Lalonde M, Gillissen-Kaesbach G, Anvret M, Horsthemke B: Imprinting mutations suggested by abnormal DNA methylation patterns in familial Angelman and Prader-Willi syndromes. *Am J Hum Genet* 1994, 54:741-747
84. Sutcliffe JS, Nakao M, Christian S, Orstavik KH, Tommerup N, Ledbetter DH, Beaudet AL: Deletions of a differentially methylated CpG island at the SNRPN gene define a putative imprinting control region. *Nat Genet* 1994, 8:52-58
85. Buiting K, Saitoh S, Gross S, Dittich B, Schwartz S, Nicholls RD, Horsthemke B: Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. *Nat Genet* 1995, 9:395-400
86. Dittich B, Buiting K, Korn B, Rickard S, Buxton J, Saitoh S, Nicholls RD, Poustka A, Winterpacht A, Zabel B, Horsthemke B: Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene. *Nat Genet* 1996, 14:163-170
87. Horsthemke B: Structure and function of the human chromosome 15 imprinting center. *J Cell Physiol* 1997, 173:237-241
88. Tilghman SM, Caspary T, Ingram RS: Competitive edge at the imprinted Prader-Willi/Angelman region? *Nat Genet* 1998, 18:206-208
89. Schumacher A, Buiting K, Zeschnick M, Doerfler W, Horsthemke B: Methylation analysis of the PWS/AS region does not support an enhancer-competition model. *Nat Genet* 1998, 19:324-325
90. Spotila LD, Sereda L, Prockop DJ: Partial isodisomy for maternal chromosome 7 and short stature in an individual with a mutation at the COL1A2 locus. *Am J Hum Genet* 1992, 51:1396-1405
91. Lefebvre L, Viville S, Barton SC, Ishino F, Keverne EB, Surani MA: Abnormal maternal behaviour and growth retardation associated with loss of the imprinted gene Mest. *Nat Genet* 1998, 20:163-169
92. Fundele RH, Surani MA: Experimental embryological analysis of genetic imprinting in mouse development. *Dev Genet* 1994, 15:515-522
93. Keverne EB, Fundele R, Narasimha M, Barton SC, Surani MA: Genomic imprinting and the differential roles of parental genomes in brain development. *Brain Res Dev Brain Res* 1996, 92:91-100
94. Skuse DH, James RS, Bishop DVM, Coppin B, Dalton P, Aamodt-Leeper G, Bacarese-Hamilton M, Creswell C, McGurk R, Jacobs PA: Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function. *Nature* 1997, 387:705-708
95. McCauley E, Ito J, Kay T: Psychosocial functioning in girls with Turner's syndrome and short stature: social skills, behavior problems, and self-concept. *J Am Acad Child Psychiatry* 1986, 25:105-112
96. McCauley E, Kay T, Ito J, Treder R: The Turner syndrome: cognitive deficits, affective discrimination, and behavior problems. *Child Dev* 1987, 58:464-473

97. Miller AP, Willard HF: Chromosomal basis of X chromosome inactivation: identification of a multigene domain in Xp11.21-p11.22 that escapes X inactivation. *Proc Natl Acad Sci USA* 1998, 95:8709-8714
98. McMahon FJ, Stine OC, Meyers DA, Simpson SG, DePaulo JR: Patterns of maternal transmission in bipolar affective disorder. *Am J Hum Genet* 1995, 56:1277-1286
99. Kato T, Winokur G, Coryell W, Keller MB, Endicott J, Rice J: Parent-of-origin effect in transmission of bipolar disorder. *Am J Med Genet* 1996, 67:546-550
100. Grigoriou-Serbanescu M, Wickramaratne PJ, Hodge SE, Milea S, Mihailescu R: Genetic anticipation and imprinting in bipolar illness. *Br J Psychiatry* 1997, 170:162-166
101. Asherson P, Walsh C, Williams J, Sargeant M, Taylor C, Clements A, Gill M, Owen M, McGuffin P: Imprinting and anticipation. Are they relevant to genetic studies of schizophrenia? *Br J Psychiatry* 1994, 164:619-624
102. Ohara K, Xu HD, Mori N, Suzuki Y, Xu DS, Wang ZC: Anticipation and imprinting in schizophrenia. *Biol Psychiatry* 1997, 42:760-766
103. Cook Jr EH, Lindgren V, Leventhal BL, Courchesne R, Lincoln A, Shulman C, Lord C, Courchesne E: Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. *Am J Hum Genet* 1997, 60:928-934
104. Morison IM, Reeve AE: A catalogue of imprinted genes and parent-of-origin effects in humans and animals. *Hum Mol Genet* 1998, 7:1599-1609
105. Wake N, Fujino T, Hoshi S, Shinkai N, Sakai K, Kato H, Hashimoto M, Yasuda T, Yamada H, Ichino K: The propensity to malignancy of dispermic heterozygous moles. *Placenta* 1987, 8:319-326
106. Linder D, McCaw BK, Hecht F: Parthenogenetic origin of benign ovarian teratomas. *N Engl J Med* 1975, 292:63-66
107. Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voute PS, Westerveld A, Versteeg R: Allelic loss of chromosome 1p36 in neuroblastoma is preferential maternal origin and correlates with N-myc amplification. *Nat Genet* 1993, 4:187-190
108. Katz F, Webb D, Gibbons B, Reeves B, McMahon C, Cheselles J, Mitchell C: Possible evidence for genomic imprinting in childhood acute myeloblastic leukaemia associated with monosomy for chromosome 7. *Br J Haematol* 1992, 80:332-336
109. Tycko B: Genomic imprinting in Wilms' tumor. *Med Ped Oncol* 1996
110. Scrabble H, Cavenne W, Ghavimi F, Lovell M, Morgan K, Sapienza C: A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. *Proc Natl Acad Sci USA* 1989, 86:7480-7484
111. Toguchida J, Ishizaki K, Sasaki MS, Nakamura Y, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, Yamamoto T: Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. *Nature* 1989, 338:156-158
112. Milunsky J, DeStefano AL, Huang XL, Baldwin CT, Michels VV, Jako G, Milunsky A: Familial paragangliomas: linkage to chromosome 11q23 and clinical implications. *Am J Med Genet* 1997, 72:66-70
113. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP: Relaxation of imprinted genes in human cancer. *Nature* 1993, 362:747
114. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. *Nature* 1993, 362:749-751
115. Steenman MJC, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. *Nat Genet* 1994, 7:433-439
116. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumor-suppressor activity of H19. *Nature* 1993, 365:764-767
117. Webber AL, Ingram RS, Levorse JM, Tilghman SM: Location of enhancers is essential for the imprinting of H19 and Igf2 genes. *Nature* 1998, 391:711-715
118. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM: Disruption of imprinting caused by deletion of the H19 gene region in mice. *Nature* 1995, 375:34-39
119. Okamoto K, Morison IM, Taniguchi T, Reeve AE: Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms' tumorigenesis. *Proc Natl Acad Sci USA* 1997, 94:5367-5371
120. Jinno Y, Yun K, Nishiwaki K, Kubota T, Ogawa O, Reeve AE, Nikawa N: Mosaic and polymorphic imprinting of the WT1 gene in humans. *Nat Genet* 1994, 6:305-309
121. Rauscher FJd: The Wt1 Wilms' tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. *FASEB J* 1993, 7:896-903
122. Chung WY, Yuan L, Feng L, Hensle T, Tycko B: Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. *Hum Mol Genet* 1996, 5:1101-1108
123. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, Yutani C, Takahashi S, Chiba Y, Ohishi S, Mukai T: Genomic imprinting of human p57<sup>KIP2</sup> and its reduced expression in Wilms' tumors. *Hum Mol Genet* 1996, 5:783-788
124. Kondo M, Matsuoaka S, Uchida K, Osada H, Nagatake M, Takagi K, Harper JW, Takahashi T, Elledge SJ, Takahashi T: Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. *Oncogene* 1996, 12:1365-1368
125. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL: Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. *Oncogene* 1995, 10:1725-1729
126. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nat Genet* 1995, 11:447-449
127. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL: M6P/IGF2 receptor: a candidate breast tumor suppressor gene. *Oncogene* 1996, 12:2003-2009
128. Yamada T, De Souza AT, Finkelstein S, Jirtle RL: Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. *Proc Natl Acad Sci USA* 1997, 94:10351-10355
129. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast Jr RC: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian, and breast carcinomas. *Proc Natl Acad Sci USA* 1999, 96:214-219
130. Korner C, Nurnberg B, Uhde M, Braulke T: Mannose 6-phosphate/insulin-like growth factor II receptor fails to interact with G-proteins: analysis of mutant cytoplasmic receptor domains. *J Biol Chem* 1995, 270:287-295
131. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, Zou T-T, Shi Y-Q, Lei J, Cottrell J, Cymes K, Biden K, Simms L, Leggett B, Lynch PM, Frazier M, Powell SM, Harpaz N, Sugimura H, Young J, Meltzer SJ: The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumours. *Nat Genet* 1996, 14:255-257
132. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, Souza RF, Meltzer SJ, Horii A: The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. *Cancer Res* 1997, 57:1851-1854
133. Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, Kwong WK, Ho JW, Yuen ST: Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. *Am J Pathol* 1998, 153:1181-1188
134. Chappell SA, Walsh T, Walker RA, Shaw JA: Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. *Br J Cancer* 1997, 76:1558-1561
135. Mills JJ, Falls JG, De Souza AT, Jirtle RL: Imprinted M6p/Igf2 receptor is mutated in rat liver tumors. *Oncogene* 1998, 16:2797-2802
136. Xu Y, Goodyer CG, Deal C, Polychronakos C: Functional polymorphism in the parental imprinting of the human IGF2R gene. *Biochem Biophys Res Commun* 1993, 197:747-754
137. Ogawa O, McNoe LA, Eccles MR, Morison IM, Reeve AE: Human insulin-like growth factor type I and type II receptors are not imprinted. *Hum Mol Genet* 1993, 2:2163-2165
138. Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers H-H: The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. *Nat Genet* 1993, 5:74-78
139. Xu YQ, Grundy P, Polychronakos C: Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. *Oncogene* 1997, 14:1041-1046
140. Wutz A, Smrzka OW, Schweifer N, Schellander K, Wagner EF,

- Barlow DP: Imprinted expression of the Igf2r gene depends on an intronic CpG island. *Nature* 1997, 389:745-749
141. Birger Y, Shemer R, Perk J, Razin A: The imprinting box of the mouse Igf2r gene. *Nature* 1999, 397:84-88
142. Smrzka OW, Fae I, Stöger R, Kruzbauer R, Fischer GF, Henn T, Weith A, Barlow DP: Conservation of a maternal-specific methylation signal at the human IGF2R locus. *Hum Mol Genet* 1995, 4:1945-1952
143. Riesewijk AM, Schepens MT, Welch TR: Van den Berg-Loonen EM, Mariman EM, Ropers HH, Kalscheuer VM: Maternal-specific methylation of the human IGF2R gene is not accompanied by allele-specific transcription. *Genomics* 1996, 31:158-166
144. Giannoukakis N, Deal C, Paquette J, Kukuviitis A, Polychronakos C: Polymorphic functional imprinting of the human IGF2 gene among individuals, in blood cells, is associated with H19 expression. *Biochem Biophys Res Commun* 1996, 220:1014-1019
145. Bunzel R, Blumcke I, Cichon S, Normann S, Schramm J, Propping P, Nothen MM: Polymorphic imprinting of the serotonin-2A (5-HT2A) receptor gene in human adult brain. *Brain Res Mol Brain Res* 1998, 59:90-92
146. Jiang S, Hemann MA, Lee MP, Feinberg AP: Strain-dependent developmental relaxation of imprinting of an endogenous mouse gene, *kvlqt1*. *Genomics* 1998, 53:395-399
147. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* 1997, 90:809-819
148. Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, Polychronakos C, Smith DI, Liu W: Loss of imprinting and allele switching of p73 in renal cell carcinoma. *Oncogene* 1998, 17:1739-1741
149. Pearsall RS, Shibata H, Brozowska A, Yoshino K, Okuda K, deJong PJ, Plass C, Chapman VM, Hayashizaki Y, Held WA: Absence of imprinting in U2AFBPL, a human homologue of the imprinted mouse gene U2afbp-rs. *Biochem Biophys Res Commun* 1996, 222:171-177
150. Hayashizaki Y, Shibata H, Hirotune S, Sugino H, Okazaki Y, Sasaki N, Hirose K, Imoto H, Okuizumi H, Muramatsu M, et al: Identification of an imprinted U2af binding protein related sequence on mouse chromosome 11 using the RLGS method. *Nat Genet* 1994, 6:33-40
151. Riesewijk AM, Schepens MT, Mariman EM, Ropers HH, Kalscheuer VM: The MAS proto-oncogene is not imprinted in humans. *Genomics* 1996, 35:380-382
152. Miller N, McCann AH, O'Connell D, Pedersen IS, Spiers V, Gorey T, Dervan PA: The MAS proto-oncogene is imprinted in human breast tissue. *Genomics* 1997, 46:509-512
153. Villar AJ, Pedersen RA: Parental imprinting of the Mas protooncogene in mouse. *Nat Genet* 1994, 8:373-379
154. Kobayashi S, Kohda T, Miyoshi N, Kuroiwa Y, Aisaka K, Tsutsumi O, Kaneko-Ishino T, Ishino F: Human PEG1/MEST, an imprinted gene on chromosome 7. *Hum Mol Genet* 1997, 6:781-786
155. Riesewijk AM, Hu L, Schulz U, Tariverdian G, Hoglund P, Kere J, Ropers HH, Kalscheuer VM: Monoallelic expression of human PEG1/MEST is paralleled by parent-specific methylation in fetuses. *Genomics* 1997, 42:236-244
156. Mitsuya K, Sui H, Meguro M, Kugoh H, Jinno Y, Niikawa N, Oshimura M: Paternal expression of WT1 in human fibroblasts and lymphocytes. *Hum Mol Genet* 1997, 6:2243-2246
157. Alders M, Hodges M, Hadjantonakis AK, Postmus J, van Wijk I, Blik J, de Meulemeester M, Westerveld A, Guillemot F, Oudejans C, Little P, Mannens M: The human Achaete-Scute homologue 2 (ASCL2/HASH2) maps to chromosome 11p15.5, close to IGF2 and is expressed in extravillous trophoblasts. *Hum Mol Genet* 1997, 6:859-867
158. Guillemot F, Caspary T, Tilghman SM, Copeland NG, Gilbert DJ, Jenkins NA, Anderson DJ, Joyner AL, Rossant J, Nagy A: Genomic imprinting of Mash2, a mouse gene required for trophoblast development. *Nat Genet* 1995, 9:235-242
159. Rachmilewitz J, Goshen R, Ariel I, Schneider T, De Groot N, Hochberg A: Parental imprinting of the human H19 gene. *FEBS Lett* 1992, 309:25-28
160. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, Tobonen V, Hedborg F, Schofield P, Flam F, Ekstrom TJ: IGF2 is parentally imprinted during human embryogenesis, and in the Beckwith-Wiedemann syndrome. *Nat Genet* 1993, 4:94-97
161. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C: Parental genomic imprinting of the human IFG2 gene. *Nat Genet* 1993, 4:98-101
162. Ogawa O, Becroft DM, Morison IM, Eccles MR, Skeen JE, Mauger DC, Reeve AE: Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism. *Nat Genet* 1993, 5:408-412
163. Dao D, Frank D, Qian N, O'Keefe D, Vosatka RJ, Walsh CP, Tycko B: IMPT1, an imprinted gene similar to polyspecific transporter, and multi-drug resistance genes. *Hum Mol Genet* 1998, 7:597-608
164. Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A, Hatada I, Mukai T, Ohashi H, Barbanti-Brodano G, Croce CM, Negrini M: Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. *Proc Natl Acad Sci USA* 1998, 95:3873-3878
165. Cooper PR, Smilgin NJ, Day CD, Nowak NJ, Reid LH, Pearsall RS, Reece M, Prawitt D, Landers J, Housman DE, Winterpacht A, Zabel BU, Pelletier J, Weissman BE, Shows TB, Higgins MJ: Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain. *Genomics* 1998, 49:38-51
166. Lee MP, Reeves C, Schmitt A, Su K, Connors TD, Hu RJ, Brandenburg S, Lee MJ, Miller G, Feinberg AP: Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5. *Cancer Res* 1998, 58:4155-4159
167. Giddings SJ, King CD, Harman KW, Flood JF, Carnaghi LR: Allele specific inactivation of insulin 1 and 2, in the mouse yolk sac, indicates imprinting. *Nat Genet* 1994, 6:310-313
168. Bennett ST, Wilson AJ, Esposito L, Bouzekri N, Undlien DE, Cucca F, Nistico L, Buzzetti R, Bosi E, Pociot F, Nerup J, Cambon-Thomsen A, Pugliese A, Shield JP, McKinney PA, Bain SC, Polychronakos C, Todd JA: Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. The IMDIAB Group. *Nat Genet* 1997, 17:350-352
169. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, et al: Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. *Nat Genet* 1995, 9:284-292
170. Qian N, Frank D, O'Keefe D, Dao D, Zhao L, Yuan L, Wang Q, Keating M, Walsh C, Tycko B: The IPL gene on chromosome 11p15.5 is imprinted in humans, and mice, and is similar to TDAG51, implicated in Fas expression, and apoptosis. *Hum Mol Genet* 1997, 6:2021-2029
171. Lee MP, Feinberg AP: Genomic imprinting of a human apoptosis gene homologue, TSSC3. *Cancer Res* 1998, 58:1052-1056
172. Morisaki H, Hatada I, Morisaki T, Mukai T: A novel gene, ITM, located between p57KIP2 and IPL, is imprinted in mice. *DNA Res* 1998, 5:235-240
173. Gould TD, Pfeifer K: Imprinting of mouse Kvlqt1 is developmentally regulated. *Hum Mol Genet* 1998, 7:483-487
174. Matsuoka S, Thompson JS, Edwards MC, Barletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57<sup>KIP2</sup>, on chromosome 11p15. *Proc Natl Acad Sci USA* 1996, 93:3026-3030
175. Kato MV, Shimizu T, Nagayoshi M, Kaneko A, Sasaki MS, Ikawa Y: Genomic imprinting of the human serotonin-receptor (HTR2) gene involved in development of retinoblastoma. *Am J Hum Genet* 1996, 59:1084-1090
176. Kato MV, Ikawa Y, Hayashizaki Y, Shibata H: Paternal imprinting of mouse serotonin receptor 2A gene Htr2 in embryonic eye: a conserved imprinting regulation on the RB/Rb locus. *Genomics* 1998, 47:146-148
177. Glenn CC, Driscoll DJ, Yang TP, Nicholls RD: Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. *Mol Hum Reprod* 1997, 3:321-332
178. Cuiat CT, Stubbs LJ, Montgomery CS, Russell LB, Rinchik EM: Phenotypic consequences of deletion of the  $\gamma 3$ ,  $\alpha 5$ , or  $\beta 3$  subunit of the type A  $\gamma$ -aminobutyric acid receptor in mice. *Proc Natl Acad Sci USA* 1994, 91:2815-2818
179. Nicholls RD, Gottlieb W, Russell LB, Davda M, Horsthemke B,

- Rinchik EM: Evaluation of potential models for imprinted and non-imprinted components of human chromosome 15q11-q13 syndromes by fine-structure homology mapping in the mouse. *Proc Natl Acad Sci USA* 1993, 90:2050-2054
180. Saitoh S, Buiting K, Rogan PK, Buxton JL, Driscoll DJ, Arneemann J, Konig R, Malcolm S, Horsthemke B, Nicholls RD: Minimal definition of the imprinting center and fixation of chromosome 15q11-q13 epigenotype by imprinting mutations. *Proc Natl Acad Sci USA* 1996, 93:7811-7815
181. Yang T, Adamson TE, Resnick JL, Leff S, Wevrick R, Francke U, Jenkins NA, Copeland NG, Brannan CI: A mouse model for Prader-Willi syndrome imprinting-centre mutations. *Nat Genet* 1998, 19: 25-31
182. MacDonald HR, Wevrick R: The necdin gene is deleted in Prader-Willi syndrome and is imprinted in human and mouse. *Hum Mol Genet* 1997, 6:1873-1878
183. Ning Y, Roschke A, Christian SL, Lesser J, Sutcliffe JS, Ledbetter DH: Identification of a novel paternally expressed transcript adjacent to snRPN in the Prader-Willi syndrome critical region. *Genome Res* 1996, 6:742-746
184. Glenn CC, Porter KA, Jong MT, Nicholls RD, Driscoll DJ: Functional imprinting and epigenetic modification of the human SNRPN gene. *Hum Mol Genet* 1993, 2:2001-2005
185. Leff SE, Brannan CI, Reed ML, Ozcelik T, Francke U, Copeland NG, Jenkins NA: Maternal imprinting of mouse Snrpn gene and conserved linkage homology with the human Prader-Willi syndrome region. *Nat Genet* 1992, 4:259-264
186. Cattanach BM, Barr JA, Evans EP, Burtenshaw M, Beechey CV, Leff SE, Brannan CI, Copeland NG, Jenkins NA, Jones J: A candidate mouse model for Prader-Willi syndrome which shows an absence of Snrpn expression. *Nat Genet* 1992, 2:270-274
187. Driscoll DJ, Waters MF, Williams CA, Zori RT, Glenn CC, Avidano KM, Nicholls RD: A DNA methylation imprint, determined by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. *Genomics* 1992, 13:917-924
188. Kim J, Ashworth L, Branscomb E, Stubbs L: The human homolog of a mouse-imprinted gene, Peg3, maps to a zinc finger gene-rich region of human chromosome 19q13.4. *Genome Res* 1997, 7:532-540
189. Joseph R, Dou D, Tsang W: Molecular cloning of a novel mRNA (neuronatin) that is highly expressed in neonatal mammalian brain. *Biochem Biophys Res Commun* 1994, 201:1227-1234
190. Dou D, Joseph R: Cloning of human neuronatin gene and its localization to chromosome-20q 11.2-12: the deduced protein is a novel "proteolipid". *Brain Res* 1996, 723:8-22
191. Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y, Bonthron DT: The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. *Proc Natl Acad Sci USA* 1998, 95:10038-10043
192. Campbell R, Gosden CM, Bonthron DT: Parental origin of transcription from the human GNAS1 gene. *J Med Genet* 1994, 31:607-614
193. Williamson CM, Schofield J, Dutton ER, Seymour A, Beechey CV, Edwards YH, Peters J: Glomerular-specific imprinting of the mouse gsalpha gene: how does this relate to hormone resistance in albright hereditary osteodystrophy? *Genomics* 1996, 36:280-287
194. Yu S, Yu D, Lee E, Eckhaus M, Lee R, Corria Z, Accili D, Westphal H, Weinstein LS: Variable and tissue-specific hormone resistance in heterotrimeric Gs protein  $\alpha$ -subunit (Gsalph) knockout mice is due to tissue-specific imprinting of the gsalph gene. *Proc Natl Acad Sci USA* 1998, 95:8715-8720
195. Daniels R, Zuccotti M, Kinis T, Serhal P, Monk M: XIST expression in human oocytes and preimplantation embryos. *Am J Hum Genet* 1997, 61:33-39
196. Goto T, Wright E, Monk M: Paternal X-chromosome inactivation in human trophoblastic cells. *Mol Hum Reprod* 1997, 3:77-80
197. Ray PF, Winston RM, Handyside AH: XIST expression from the maternal X chromosome in human male preimplantation embryos at the blastocyst stage. *Hum Mol Genet* 1997, 6:1323-1327
198. Kay GF, Barton SC, Surani MA, Rastan S: Imprinting and X chromosome counting mechanisms determine Xist expression in early mouse development. *Cell* 1994, 77:639-650
199. Norris DP, Patel D, Kay GF, Penny GD, Brockdorff N, Sheardown SA, Rastan S: Evidence that random and imprinted Xist expression is controlled by preemptive methylation. *Cell* 1994, 77:41-51
200. Zuccotti M, Monk M: Methylation of the mouse Xist gene in sperm and eggs correlates with imprinted Xist expression and paternal X-inactivation. *Nat Genet* 1995, 9:316-320
201. Hagiwara Y, Hirai M, Nishiyama K, Kanazawa I, Ueda T, Sakaki Y, Ito T: Screening for imprinted genes by allelic message display: identification of a paternally expressed gene impact on mouse chromosome 18. *Proc Natl Acad Sci USA* 1997, 94:9249-9254
202. Deltour L, Montagutelli X, Guenet JL, Jami J, Paldi A: Tissue- and developmental stage-specific imprinting of the mouse proinsulin gene. *Ins2. Dev Biol* 1995, 168:686-688
203. Zhan S, Shapiro DN, Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. *J Clin Invest* 1994, 94:445-448
204. Zhan S, Shapiro DN, Helman LJ: Loss of imprinting of IGF2 in Ewing's sarcoma. *Oncogene* 1995, 11:2503-2507
205. Rainier S, Dobry CJ, Feinberg AP: Loss of imprinting in hepatoblastoma. *Cancer Res* 1995, 55:1836-1838
206. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ: Expression, promoter usage, and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. *Oncogene* 1995, 11:221-229
207. Elkin M, Shevelev A, Schulze E, Tykocinsky M, Cooper M, Ariel I, Pode D, Kopf E, de Groot N, Hochberg A: The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. *FEBS Lett* 1995, 374:57-61
208. Rachmilewitz J, Elkin M, Looijenga LH, Verkerk AJ, Gonik B, Lustig O, Werner D, de Groot N, Hochberg A: Characterization of the imprinted IPW gene: allelic expression in normal and tumorigenic human tissues. *Oncogene* 1996, 13:1687-1692
209. McCann AH, Miller N, O'Meara A, Pedersen I, Keogh K, Gorey T, Dervan PA: Biallelic expression of the IGF2 gene in human breast disease. *Hum Mol Genet* 1996, 5:1123-1127
210. Wu HK, Squire JA, Catzavelos CG, Weksberg R: Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. *Biochem Biophys Res Commun* 1997, 235:123-129
211. Douc-Rasy S, Barrois M, Fogel S, Ahomadegbe JC, Stéhelin D, Coll J, Riou G: High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. *Oncogene* 1996, 12:423-430
212. Arima T, Matsuda T, Takagi N, Wake N: Association of IGF2 and H19 imprinting with choriocarcinoma development. *Cancer Genet Cytogenet* 1997, 93:39-47
213. Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M, Toyota T: Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. *Cancer Lett* 1996, 107:105-108
214. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, Ito K, Takagi H: Loss of H19 imprinting in esophageal cancer. *Cancer Res* 1996, 56:480-482
215. Wu MS, Wang HP, Lin CC, Sheu JC, Shun CT, Lee WJ, Lin JT: Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma. *Cancer Lett* 1997, 120:9-14
216. Uyeno S, Aoki Y, Nata M, Sagisaka K, Kayama T, Yoshimoto T, Ono T: IGF2 but not H19 shows loss of imprinting in human glioma. *Cancer Res* 1996, 56:5356-5359
217. Takeda S, Kondo M, Kumada T, Koshikawa T, Ueda R, Nishio M, Osada H, Suzuki H, Nagatake M, Washimi O, Takagi K, Takahashi T, Nakao A: Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. *Oncogene* 1996, 12:1589-1592
218. Kim KS, Lee YI: Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. *Cancer Lett* 1997, 119:143-148
219. Wu HK, Weksberg R, Minden MD, Squire JA: Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. *Biochem Biophys Res Commun* 1997, 231:466-472
220. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP: Loss of imprinting in disease progression in chronic myelogenous leukemia. *Blood* 1998, 91:3144-3147
221. Suzuki H, Veda R, Takahashi T: Altered imprinting in lung cancer. *Nat Genet* 1994, 6:332-333
222. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T:

- Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. *Oncogene* 1995, 10: 1193-1198
223. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W: Activation of p73 silent allele in lung cancer. *Cancer Res* 1998, 58:2347-2349
  224. Albrecht S, Waha A, Koch A, Kraus JA, Goodyer CG, Pietsch T: Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma. *J Neuropathol Exp Neurol* 1996, 55:1270-1276
  225. Hodzic D, Delacroix L, Willemsen P, Bensbaho K, Collette J, Broux R, Lefebvre P, Legros JJ, Grooteclaes M, Winkler R: Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma. *Horm Metab Res* 1997, 29:549-555
  226. Yaginuma Y, Nishiwaki K, Kitamura S, Hayashi H, Sengoku K, Ishikawa M: Relaxation of insulin-like growth factor-II gene imprinting in human gynecologic tumors. *Oncology* 1997, 54:502-507
  227. Jarrard DF, Bussemakers MJG, Bova GS, Isaacs WB: Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. *Clin Cancer Res* 1995, 1:1471-1478
  228. Nonomura N, Nishimura K, Miki T, Kanno N, Kojima Y, Yokoyama M, Okuyama A: Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. *Cancer Res* 1997, 57:2575-2577
  229. van Gurp RJ, Oosterhuis JW, Kalscheuer V, Mariman EC, Looijenga LH: Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. *J Natl Cancer Inst* 1994, 86:1070-1075
  230. Vu TH, Yballe C, Boonyanit S, Hoffman AR: Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. *J Clin Endocrinol Metab* 1995, 80:1670-1676

## Genomic structure of the human M6P/IGF2 receptor

J. Keith Killian, Randy L. Jirtle

Departments of Radiation Oncology and Pathology, Box 3433, Duke University Medical Center, Durham, North Carolina 27710, USA

Received: 14 July 1998 / Accepted: 3 September 1998

The human mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene located at 6q26 (Rao et al. 1994) encodes for a multifunctional receptor that possesses distinct binding sites for phosphomannosyl glycoproteins and IGF2 (MacDonald et al. 1988; Morgan et al. 1987), retinoic acid (Kang et al. 1997), and urokinase-type plasminogen activator receptor (uPAR; Nykjaer et al. 1998). The receptor is involved in fetal development, tumor suppression, maternal regulation of intrauterine growth, and has recently been associated with the development of human cognitive ability (Chorney et al. 1998; De Souza et al. 1997; Kornfeld 1992; Wang et al. 1994). To facilitate further genetic analyses of the human M6P/IGF2R, we have determined its complete genomic organization, defined the intron-exon boundary sequences, and designed intronic oligonucleotides for PCR amplification of the 48 exons included in the 136-kb genomic sequence.

The M6P/IGF2R is a chimeric receptor possessing binding sites for four distinct classes of ligands (Kang et al. 1997; Nykjaer et al. 1998; MacDonald et al. 1988; Morgan et al. 1987). The M6P binding site enables the M6P/IGF2R to target to the lysosomes both newly synthesized lysosomal enzymes from the Golgi and phosphorylated proteolytic enzymes endocytosed from the extracellular environment (Kornfeld 1992). Furthermore, the latent complex of transforming growth factor beta (TGF $\beta$ ), a potent growth inhibitor, binds to the M6P/IGF2R through these M6P binding sites, thereby facilitating its activation by plasmin (Dennis and Rifkin 1991). The effectiveness of TGF $\beta$  activation may be further enhanced by the direct binding of uPAR to the M6P/IGF2R (Nykjaer et al. 1998). The mammalian M6P/IGF2R also contains an independent IGF2 binding site that is absent in chickens (Zhou and Sly 1995). IGF2 binding to the M6P/IGF2R leads to lysosomal degradation rather than intracellular signaling, a process mediated by both the IGF1 and the insulin receptors (Kornfeld 1992). Therefore, loss of M6P/IGF2R function would be predicted to increase the extracellular concentration of IGF2, decrease the level of active TGF $\beta$ , and increase the secretion of proteolytic enzymes. These biological effects suggest the M6P/IGF2R functions normally as a tumor suppressor.

A number of reports now strongly support this postulate for a wide variety of human tumors. Briefly, the M6P/IGF2R is mutated in 60% of dysplastic liver lesions and HCCs in patients with or without hepatitis virus (HV) infection (De Souza et al. 1995a, 1995b; Yamada et al. 1997). Its inactivation also plays a prominent role in the early stage of breast cancer development (Hankins et al. 1996), and increased expression of the wild-type receptor in breast cancer cell lines leads to apoptosis (Oates et al. 1998). Furthermore, the M6P/IGF2R gene contains a poly-G region that is a common mutational target in colon, gastric, and endometrial tumors with mismatch repair deficiencies and microsatellite instability (Souza et al. 1996). Thus, M6P/IGF2R inactivation is a frequent oncogenic event that occurs early in carcinogenesis.

A full parental complement of autosomal genes is inherited by

all offspring, but not all are biallelically expressed. The phenomenon of monoallelic expression of the same parental allele is called genomic imprinting (Surani 1998). The *M6p/Igf2r* gene is imprinted in mice (Barlow et al. 1991) and is expressed only from the maternal allele in all tissues except potentially the brain (Hu et al. 1998). In contrast, imprinting of the M6P/IGF2R gene is a polymorphic trait in humans, with most people having biallelic expression in all tissues (Xu et al. 1993). Although imprinting of the M6P/IGF2R may have provided an evolutionary advantage to the mother during the emergence of mammalian intrauterine growth (Haig and Graham 1991), monoallelic expression of this gene would also be predicted to increase cancer susceptibility. In support of this postulate, Xu et al. and associates (1997) have recently demonstrated M6P/IGF2R imprinting in 50% of Wilms' tumors.

Plomin and his colleagues have also identified the M6P/IGF2R as a putative "IQ gene" (Chorney et al. 1998). By comparing Caucasian children with an IQ of 160 or higher with those with an average IQ, they showed that the M6P/IGF2R is linked to human cognitive ability. If a polymorphism in the M6P/IGF2R coding sequence or its regulatory region is subsequently shown to functionally affect IQ, it would be the first identified gene known to contribute to intelligence. Thus, the M6P/IGF2R plays a fundamental role in biological processes ranging from embryogenesis to carcinogenesis. How the M6P/IGF2R could possess such diverse biological functions is an intriguing enigma that remains to be solved.


To facilitate future studies on the human M6P/IGF2R, we have characterized its complete genomic structure. The human cDNA sequence was divided into 48 exons based upon the mouse genomic structure (Szebenyi and Rotwein 1994), and PCR primers were designed to traverse these putative introns. All the introns except 1, 2, and 4 were amplified from human genomic DNA with either long-template PCR (Boehringer Mannheim Corp., Indianapolis, Ind.) or traditional PCR (Qiagen, Inc, Santa Clarita, Calif.). PCR products were sequenced on an ABI automated sequencer (Perkin-Elmer Corp., Foster City, Calif.). The sizes of introns 1 and 2 and their 5' and 3' boundary sequences were previously defined (Riesewijk et al. 1996; Smrzka et al. 1995); this information is available on GenBank (Accession Nos. X83699, X83700, and X83701). To sequence intron 4, human BAC clones (174E20 and 650K6) were first obtained by probing filters from Research Genetics, Inc. (Huntsville, Ala.) with an RT-PCR product spanning exons 1 to 6. A 13-kb stretch of DNA containing intron 4 was then PCR amplified from this BAC clone and the exon-intron boundaries sequenced. With the exception of intron 15, all exon-intron splice sites (93/94) conformed to the AG/GT rule (Mount 1982). Interestingly, the single intron splice site exception is also present in the mouse *M6p/Igf2r* homolog (Szebenyi and Rotwein 1994).

Intron sizes were determined by sequencing the entire intron or estimated by electrophoresis. Twenty introns were sequenced entirely (that is, introns 8, 9, 13–17, 21, 23, 24, 27, 28, 32–34, 37, 38, 42, 43, and 46), and at least 100 bp of flanking intronic sequence were determined for the remaining introns. The entire human M6P/IGF2R gene was then reconstructed with the use of the previously

Table 1. Human M6P/IGF2R intron-exon boundaries.

Exon	cDNA (nt)	Exon size (bp)	5' splice donor	Intron size (kb)	3' splice acceptor	Intron phase <sup>a</sup>
1	1	296	CAGgtgggtgcccgcce	22.0	tttctcttccagTTA	2
2	296	140	TGGgtaagtagaactacc	17.0	ttctctccaaatagGTG	1
3	437	125	CTGgtgagtcacacag	1.5	atttttttaaatagGGA	0
4	562	99	GAGgtaacatgggaactt	13.0	cttccctctccagGTG	0
5	661	133	TAGgtatgaatcttgtg	2.0	atacatgatttcagACA	1
6	794	130	CAGgtcagtcaggcctc	2.2	atgtgctctccagGCT	2
7	924	106	GAGgtaagtgaactgtct	2.7	cattgtcctgatagGGC	0
8	1030	163	GAGgtaagcaggtgcttt	0.227	tttcctgttttagGTT	1
9	1193	166	CCGgtacgtcaacaacct	1.315	ttcacaaaaatctagATA	2
10	1359	104	CAGgtaagtgtgcctgg	5.5	tcttgaattgtgcagGTA	1
11	1463	165	CAGgtactgcctccttg	2.5	ttgttttttacagAAC	1
12	1628	141	TGGgtgagttgtgctgg	1.2	cccttctctccagATA	1
13	1769	144	CAGgtaaaaattttaaa	1.095	tttcccatgtacagGTG	1
14	1913	138	CAGgtctgtgtccaaagca	0.614	tttaactctttaaGGT	1
15	2051	148	AAgcaagtagcttctca	0.511	cgtgtttaaattcagTGA	2
16	2199	178	CAGgtaggaatgtttgtc	0.456	ctgccgtgggattagGAA	0
17	2377	116	CAGgtaggcagagtcag	0.468	gcttgaatttttagTCT	2
18	2493	169	CAGgtgaatctgttttca	2.0	ctggttttcttgcagGGC	0
19	2662	180	CTGgtgaagcactgctgc	5.0	gatttgccattcagAAC	0
20	2842	102	CAGgtactgtgtctttca	1.5	ttttgttctctgtagGCT	0
21	2944	102	ATGgtgaagcagcatatga	0.78	ccgtctgacctgcagTTT	0
22	3046	193	AAggtgagctcagagcca	1.6	cttctgtttacagGTA	1
23	3239	171	CCGgtaaagccgtgcggc	0.781	tttgtgtgttcagACC	1
24	3410	144	AGGgtgagttctccttgg	0.105	attctgttctccagGCA	1
25	3554	176	TCGgtgtgtgttcagacc	0.8	tgattttattacagGGC	0
26	3730	88	AAggtaggactgggcctg	1.5	tccatgttctgaagGGG	1
27	3818	216	CAGgtaccattgtttgtc	0.771	tctcttctttacagGTC	1
28	4034	131	CGGgtgagcatgtaccga	0.271	tcttaactttttagCCA	0
29	4165	98	CAAgtaatccatggatg	3.0	ttttctttttcagAGA	2
30	4265	137	CTGgtgagagaggcctc	1.5	tgtctgtgtctgcagAGC	1
31	4400	191	GTGgtgaaggactgttcc	1.5	tgtgtgtgtgttagAAC	0
32	4591	127	CAGgtgagaggtggtgcc	0.732	tcttcaccctacagGAC	1
33	4718	120	TGGgtgagtgctgtgtgc	0.327	tccctgtgtgtgcagGGG	1
34	4838	257	GCGgtgagttttcagatg	0.286	tttctacttaacagACC	0
35	5095	219	ATAgtaagtatgacaaat	2.0	tcgctctgttttagGAT	0
36	5344	150	ATGgtgaagtgtggcctg	2.3	tcttctggcaacagGGA	0
37	5464	162	AAggtaatgcgttcaccc	1.233	atggttttgtccagGTG	0
38	5626	208	CAGgtaaattttgaaat	0.341	tcttcttcttcagAAA	1
39	5834	147	ACTgtgagtaggacggct	3.6	centacactccccagCAA	1
40	5981	235	CTCgtgagtgccctccca	1.0	tgtgtctgtttctagGTA	2
41	6216	137	TAGgtgaagcctgtgggt	3.0	atttgtgtttcagGTG	1
42	6353	115	GAGgtcaggagactgggg	0.957	cttccctctcctagGTT	2
43	6468	147	TAAgtaatgaaacgttt	0.662	tttctgtctctcagGCT	2
44	6615	188	AAggtaatccgtggcttc	6.5	cttcccgatgacagACG	1
45	6803	187	GGGgtgagtatgaaatcc	5.5	gtgacgtccttgcagGGT	2
46	6990	153	GAGgtgaagcgggtgcag	1.081	ccctttttttatagGGA	2
47	7143	70	AAggtaatttctgtgc	1.8	gttgatccctggcagGTG	0
48	7213	1878				

<sup>a</sup> Intron-exon splice junctions are categorized as phase 0, uninterrupted codon; phase 1, codon interrupted after the first nucleotide; and phase2, codon interrupted after the second nucleotide.



**Fig. 1.** Genomic organization of the human M6P/IGF2R. **A)** The 48 exons of the human M6P/IGF2R are distributed over approximately 136 kb. **B)** The mRNA is subdivided into exons, and the ACAA tetranucleotide insertion (Hol et al. 1992) and the (GT)<sub>n</sub> dinucleotide (Goto et al. 1992) polymorphic sites in the 3'-UTR (exon 48) are shown. The mRNA is also aligned with the protein sequence, which is divided into 15

structural repeats, each of approximately 150 amino acids; a 27-amino acid gap between repeats 14 and 15 (gap); a single 23-amino acid transmembrane domain (tm); and a 164-amino acid cytoplasmic tail (cyto) (Morgan et al. 1987). Repeats 3 and 9 (M) contain the M6P-binding domains, and repeat 11 (G) forms the IGF2-binding domain (Dahms et al. 1993; Schmidt et al. 1995).

**Table 2.** Intronic oligonucleotides for PCR amplification of the 48 human M6P/IGF2R exons.

Exon	F1 (5' to 3')	R1 (5' to 3')	Nested Primer (5' to 3') <sup>a</sup>
1	gctgtcactgtgacgcgggttc	accgcgagcggagcctgcctc	gccgcgcgtgcgcgtgtgcF2
2	ctagtgtgtggcagtttaagcaaatg	attgccaatccagtaatttcagg	gataaatcagtgacattgacaagtgtF2
3	gggttatgtatgtttatagcctcg	ttaaagaataacatcaagtcctctg	aatacatcaagtgccctgtgtggacR2
4	tttatttttagtagcctttactgcatctca	gataaagttcccccagagatatacttc	ccagagtatacttataagcatgR2
5	ctgattgaccaagatgtatctg	gaaagggcaagatattgaagccatag	cctcaccaccacccccctcagR2
6	ctaagggtacgtgtgattatcactc	gaaagtcaggtctctgtctggag	aaacgccacagcagctggaggR2
7	ggcaacatagtaatttggatgtac	caaccggcgtactgtgcgc	gtgcgccacattagtgatcagR2
8	gtggaaaatctgattaaagctgcatg	cctttctctaagcagcgcgc	caggaggcagaagcactctgR2
9	gactaagttaagactgtaattcttaatacc	cgcacagaggtgtttgacgtac	aatacctattcataaaaacagcctcF2
10	cccaaacacattgtgtgtgtatc	acaagcacatgcccatgaatgc	gcaaaagaggaggggcgtgaacR2
11	gctgttctcaattttgttcacg	gaaaatgttccatgacatgtggac	gactaagaccggcatggcaaggR2
12	gtgactcagagaatcagcattgc	ctaactcattccaaactggatgcc	gaaaagcatcactgatcttccR2
13	gtcactctttgtctgctgtgatgac	atatgaagaatgcaggacactctgg	caggacactctgcagaagccR2
14	gtccctccaagtctactctagc	gtgggttccaaagtcacattaaagcag	cacattaaagcagaggtctcgtR2
15	gttggaaacctcctgggaag	cttagcataatgctcagaatgaaac	ctaagaatgaaacagagctgagaagcR2
16	gtgactctcagctgctcagc	cacagcgtatgagtatcctcagg	glatcctcaggagcgcgatgR2
17	cicattgggaacctgtctctcg	cagcaacacttgcacactcagc	caacctcagcattgtaccagR2
18	gtaagctttacttcccaactacatag	ctccactaagtcatggaattagg	taggaggggcaaaaggagcaagcR2
19	ccaccaataacgaatcagctg	cacataaggcaacgtcagtc	aatgcagcagtgaaggtccacR2
20	agtattctttgtttctatcaagttcc	gtccagcagcagcagctcagc	ctcagcagcagggccaggtgR2
21	gtgctgtatgtatgttttctctgtg	gtgacttcaatgaatcactctcc	ctgtttcaaaagcaactggaaatgR2
22	tcttctgtgtgtgagatcagagg	ctacactcaggaaggtgcattggc	atggccagccacagagccacR2
23	ctgcactgtgtgtgtggctgc	gaactctgaccgcctctcagttc	gaccggcctctcagttctaggR2
24	gcagttcttgagtgctcacaagg	caaatgctctcaataaagaacagacgc	cagacgccaatcaagagaccagR2
25	gagcatttgactcaaggtcatcgc	gaaatgggaaatggagtcacccg	gggacaacatctcattgtggtcR2
26	gattacaggtgtgtgagccacgtg	catcgttcagaaactgtgctactctatc	aaaatgactgttagggcaagcR2
27	cgtgtgtgtgtgtgagttgcc	ctcaagggaataattctctcagc	gttgaggttgccttactctcF2
28	gtgtcactatcttaggctaag	aatatgatccagcagcctgag	gtttgacagcctaggagcF2
29	caaaagtaataaactaaagtgttgcattctcac	gcaaaatcatacgaattgtctgtcc	gtttgtcattctcattttatatgtgF2
30	acgaccaagcctaactaactgc	ctctcaccagtgtcgtgctgtg	cctgtgatacactcactgcaaacR2
31	tgatgaagttctgttctagcctg	gcagaaggtgcaggaacagtcctc	gggagtcactaaagcgaactcF2
32	ccactgtgaagttgaaatcatgatagac	caccgtctctcactgcgcgtg	gctgggtgttaacgactggtcacR2
33	gcctcccaagtcagctcc	gcaaaagagactgaggacaacc	ccctggagtcactgtgtccF2
34	gaaattgatgtcctgacttgcc	gcactgtgagatgcactctcc	catcagaataatggccatcagctF2
35	ggatgacctagtgtgtgattagg	gcgaagagttatcactaaagtcttg	gtcttgcgaataatattctccaccttR2
36	ccttgggaatgttaatttctg	cgcactttctgtgtgtctagcc	gccttggctcactaacccgcagR2
37	tgtaactgtctatctccatgacc	cagcactctggcactgtgtacac	gtacactgtcaccgcaacgR2
38	actttgagactcgggtgc	cagcttcttctgtctgtatgtc	gctgccactctgctcagggcF2
39	ctgaggtgatgtgctgctggcg	ctcagtgatgaatcgagccttgac	cgaggcacagctgccaactgF2
40	gcatagacacagtgacagctgatac	gcagctgtgaattcacatgc	gttcacatgtgagggtgtggcR2
41	caggggcagagacgtcacttgc	caacttcccggttcagatgctg	gttcagatgtgctccttggaacR2
42	gaattgacaggtgtgagccaactg	ctccagtatgctcactgcacag	gcacagctcccgctctgagccR2
43	gttttgacgtcttccctatgtctg	gcattgtgtgttaatttgaacac	catttcacagctcagaaggaacgR2
44	ctgagggtttatgtcatgaaagcc	ccttcttggagggaagttaaatgtg	gaagttaaatgtggaactttgtgggR2
45	ggagctaaagctcagctgtctctg	cacttattcttaagggaagatgtgg	gatgtgggttacaaagtgtcaagcR2
46	caggtttgtgctgtggcagc	tagctatggaggcatgcatcc	catcaccgcccccacctoR2
47	ccatgccctctacactggag	cctgatgagaacgacatggacagcg	ggcaggccttcaagagactcgR2
48	ggctcagctgtgtctctgtgtg	gcctgacctctcaccctc	gcatactcagtggaagtcR2

<sup>a</sup> Nested primers F2 and R2 should be paired with R1 and F1, respectively, during second-round PCR.

characterized genomic sequence for exons 1 to 3 (Riesewijk et al. 1996; Smrzka et al. 1995) and the sequence from our overlapping PCR-generated products. The complete set of intron-exon boundary sequences for the M6P/IGF2R and all of the intron and exon sizes are presented in Table 1. The codon position that is interrupted by the intron is indicated by the intron phase. The intron-exon splice junctions for the human M6P/IGF2R are identical in position to those in the mouse (Szebenyi and Rotwein 1994). The total size of the human M6P/IGF2R gene is estimated to be 136 kb (Table 1, Fig. 1). This is approximately 43 kb larger than that for the mouse gene, and introns 2 and 4 account for much of this increased size. The M6P and IGF2 receptor binding domains are also assigned to the appropriate exons (Fig. 1). The intron-exon boundary sequences were deposited with GenBank (Accession Nos. AF069333-378), and will also be available on the M6P/IGF2R Information Core (<http://www.radonc.duke.edu/~jirtle/homepage.html>).

We have also designed intronic oligonucleotides for PCR amplification of the 48 human exons, including nested primers to allow for second-round DNA amplification (Table 2). DNA amplification from formalin-fixed, paraffin-embedded tissues requires primers that minimize the size of the amplified regions while including the splice sites flanking the exons. All 48 primer

sets have been successfully employed to PCR amplify DNA isolated from either frozen tissue or formalin-fixed, paraffin-embedded samples. These nested primer sets yield a single PCR product approximately the size of the exon (Table 1) plus 80 bp. The PCR conditions used for all primer sets were 94°C × 20 s, 55°C × 30 s, and 72°C × 20 s for the 25-cycle first round and 30-cycle second round DNA amplifications.

In conclusion, we have determined the genomic structure and the intron-exon boundaries of the human M6P/IGF2R. These sequence data have been used to design PCR primers that allow for the systematic analysis of the 48 exons that encode for the human M6P/IGF2R gene. This should greatly facilitate linkage, phylogenetic, functional, and mutational analyses of the M6P/IGF2R, thereby enhancing further our understanding of this receptor's function in evolution, cancer biology, and human intelligence.

**Acknowledgments.** We thank Angus De Souza, Greg Falls, Mar-chuk, David Pulford, and Tomoya Yamada for their technical assistance; James V. Jirtle for M6P/IGF2R webpage design; Helena Abushama of the Duke Genetics Facility for help with BAC clone screening; and Marnee Baker and Scott Langdon for help with DNA sequencing. This study was supported by National Institutes of Health grants CA25951 and FS08823, Department of Defense Grant DAMD17-98-1-8305, Sumitomo Chemical Company, Ltd., and Zeneca Pharmaceuticals, Ltd.

## References

- Barlow DP, Stöger R, Herrmann BG, Saito K, Schweifer N (1991) The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* 349, 84–87
- Chorney MJ, Chorney K, Seese N, Owen MJ, Daniels J, et al. (1998) A quantitative trait locus associated with cognitive ability in children. *Psych Sci* 9, 159–166
- Dahms NM, Rose PA, Molkentin JD, Zhang Y, Brzycki MA (1993) The bovine mannose 6-phosphate/insulin-like growth factor II receptor, the role of arginine residues in mannose 6-phosphate binding. *J Biol Chem* 268, 5457–5463
- Dennis PA, Rifkin DB (1991) Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. *Proc Natl Acad Sci USA* 88, 580–584
- De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, et al. (1995a) Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. *Oncogene* 10, 1725–1729
- De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL (1995b) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nat Genet* 11, 447–449
- De Souza AT, Yamada T, Mills JJ, Jirtle RL (1997) Imprinted genes in liver carcinogenesis. *FASEB J* 11, 60–67
- Goto J, Figlewicz DA, Marineau C, Khodr N, Rouleau GA (1992) Dinucleotide repeat polymorphism at the IGF2R locus. *Nucleic Acids Res* 20, 923
- Haig D, Graham C (1991) Genomic imprinting and the strange case of the insulin-like growth factor II receptor. *Cell* 64, 1045–1046
- Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, et al. (1996) M6P/IGF2 receptor: a candidate breast tumor suppressor gene. *Oncogene* 12, 2003–2009
- Hol FA, Geurds MP, Hamel BC, Mariman EC (1992) Improving the polymorphism content of the 3' UTR of the human IGF2R gene. *Hum Mol Genet* 1, 347
- Hu JF, Oruganti H, Vu TH, Hoffman AR (1998) Tissue-specific imprinting of the mouse insulin-like growth factor II receptor gene correlates with differential allele-specific DNA methylation. *Mol Endocrinol* 12, 220–232
- Kang JX, Li Y, Leaf A (1997) Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. *Proc Natl Acad Sci USA* 94, 13671–13676
- Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. *Annu Rev Biochem* 61, 307–330
- MacDonald RG, Pfeffer SR, Coussens L, Tepper MA, Brocklebank CM, et al. (1988) A single receptor binds both insulin-like growth factor II and mannose 6-phosphate. *Science* 239, 1134–1137
- Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, et al. (1987) Insulin-like growth factor II receptor as a multifunctional binding protein. *Nature* 329, 301–307
- Mount SM (1982) A catalogue of splice junction sequences. *Nucleic Acids Res* 10, 459–472
- Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, et al. (1998) Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. *J Cell Biol* 141, 815–828
- Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, et al. (1998) The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. *Breast Cancer Res Treat* 47, 269–281
- Rao PH, Murty VVVS, Gaidano G, Hauptschein R, Dalla-Favera R, et al. (1994) Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. *Cytogenet Cell Genet* 66, 272–273
- Riesewijk AM, Schepens MT, Welch TR, Van den Berg-Loonen EM, Mariman EM, et al. (1996) Maternal-specific methylation of the human *IGF2R* gene is not accompanied by allele-specific transcription. *Genomics* 31, 158–166
- Schmidt B, Kiecke-Siensen C, Waheed A, Bräulke T, von Figura K (1995) Localization of the insulin-like growth factor II binding site to amino acids 1508–1566 in repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor. *J Biol Chem* 270, 15975–14982
- Smrzka OW, Fae I, Stöger R, Kruzbauer R, Fischer GF, et al. (1995) Conservation of a maternal-specific methylation signal at the human *IGF2R* locus. *Hum Mol Genet* 4, 1945–1952
- Souza RF, Appel R, Yin J, Wang S, Smolinski KN, et al. (1996) The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumours. *Nat Genet* 14, 255–257
- Surani MA (1998) Imprinting and the initiation of gene silencing in the germ line. *Cell* 93, 309–312
- Szebenyi G, Rotwein P (1994) The mouse insulin-like growth factor II/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: molecular cloning and genomic organization. *Genomics* 19, 120–129
- Wang ZQ, Fung MR, Barlow DP, Wagner EF (1994) Regulation of embryonic growth and lysosomal targeting by the imprinted *Igf2/Mpr* gene. *Nature* 372, 464–467
- Xu Y, Goodyer CG, Deal C, Polychronakos C (1993) Functional polymorphism in the parental imprinting of the human *IGF2R* gene. *Biochem Biophys Res Commun* 197, 747–754
- Xu YQ, Grundy P, Polychronakos C (1997) Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. *Oncogene* 14, 1041–1046
- Yamada T, De Souza AT, Finkelstein S, Jirtle RL (1997) Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. *Proc Natl Acad Sci USA* 94, 10351–10355
- Zhou M, Sly WS (1995) Cloning and expression of the cDNA of chicken cation-independent mannose-6-phosphate receptor. *Proc Natl Acad Sci USA* 92, 9762–9766